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Abstract 
 
 This study investigated the effects that sample processing had on PBMC gene 
expression profiles. Specifically, two vacutainer types were used in this study; sodium 
heparin CPT vacutainers and “standard” sodium heparin vacutainers as well as two 
freezing devices; CoolCell and programmable rate-controlled freezer. Biogen’s clinical 
trials collect whole blood in sodium heparin CPT vacutainers and cryopreserve PBMCs 
using a CoolCell device because both are more convenient and economical for the 
site.  The results revealed that when RNA from freshly isolated PBMCs from both 
vacutainer types were compared 21 DEGs were identified. Regardless of the vacutainer 
type, when comparing RNA from freshly isolated PBMCs to RNA from thawed 
cryopreserved cells using a CoolCell device ~50 DEGs were identified but only ~30 
DEGs were found when RNA from freshly isolated PBMCs were compared to RNA from 
rate-control frozen PBMCs. Additional testing needs to be performed to better appreciate 
when to use each vacutainer. My results suggest that a rate-controlled freezer causes less 
DEGs than a CoolCell and that about 74% of the cryopreservation-related genes (17/23) 
were common regardless of vacutainer type or freezing device used. The data from this 
project will assist in the design of scientifically-based “Best Practices” needed for 
appropriate sample processing of PBMCs. 
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Chapter I 
Introduction 
 
Hypothesis  
 The isolation of peripheral blood mononuclear cells (PBMCs) from venous blood 
for research and clinical analyses has become a common practice (Koncarevit, et al., 
2014). Fan & Hedge (2005) has suggested that for clinical research, peripheral blood has 
been an appealing tissue type to collect as it exemplifies one of the most extensively used 
and easily obtained sample types in clinical settings. The collection of blood from donors 
is considered to be minimally invasive if standard clinical procedures are followed (Fan 
& Hegde, 2005). Isolating PBMCs from peripheral blood is ideal for assessing any 
changes in gene expression patterns and sample processing has been shown to affect gene 
expression (Debey et al.2004).  
 Recently, research by Lempicki et al. (2013) has shown that fresh PBMCs 
isolated by ficoll-density centrifugation from anti-coagulated whole blood collected in 
Acid Citrate Dextrose (ACD) vacutainers had a different gene expression pattern than 
PBMC aliquots that had been cryopreserved, stored and thawed. More specifically, this 
research group identified a total of 1,367 genes whose expression after 14 months of 
storage was affected (increased or decreased) >3 fold in PBMCs following isolation, 
cryopreservation and thawing as compared to freshly isolated PBMC aliquots that did not 
undergo cryopreservation. Sixty-six of these genes were shared among two or more 
major stress-related cellular pathways (stress responses, immune activation and 
!  #!
apoptosis/cell death). 
 Biogen’s clinical trials currently uses Cell Preparation Tube (CPT) vacutainers 
containing the anti-coagulant, sodium heparin, as a means to isolate PBMCs from whole 
blood for biomarker discovery when multiple clinic trial sites are involved.  Therefore, 
Biogen’s Biobank is interested in determining the effect that the preservative, sodium 
heparin, has on gene expression of freshly isolated, cryopreserved and thawed PBMCs 
when whole blood is collected in a “standard” vacutainer that contains sodium heparin as 
compared to having whole blood collected in a CPT vacutainer that has sodium heparin 
inside.  Additionally, this study will examine the effect that two different 
cryopreservation devices, e.g., programmable rate-controlled freezers and CoolCells have 
on PBMC gene expression. Both are commonly used to cryopreserve PBMCs. The rate-
controlled freezers are commercially available programmable freezers that lower the 
temperature of PBMC-containing cryovials by -1oC/minute until the temperature inside 
the vial reaches -150oC. Once the cryovials reach -150oC, the cryovials are transferred to 
long-term storage in freezers that maintain temperature at <-150oC.   Whereas, CoolCells 
are well-insulated commercial devices that require placing the PBMC-containing 
cryovials inside the device and then placing the device in a -80oC freezer so that the 
cryovials containing the PBMCs decrease their temperature -1oC/minute until it reaches -
80oC.  Once the temperature inside the vials reach -80oC while inside a CoolCell, which 
takes a minimum of 4 hours, the cryovials then need to be transferred to a freezer for 
long-term storage that maintains temperature at <-150oC.  The rate-controlled freezer is 
considerably more expensive than the CoolCell.   As a result, Biogen typically has their 
clinical trial sites use the less expensive and smaller capacity CoolCell to cryopreserve 
!  $!
PBMCs.  Therefore, it is important to determine if freezing PBMCs using a CoolCell 
device produces a different gene expression pattern than when a rate-controlled freezer is 
used.  
 For my project, I expect to see differences in the gene expression pattern between 
the freshly isolated PBMCs from the whole blood collected in a sodium heparin 
vacutainer versus freshly isolated PBMCs from sodium heparin CPT vacutainers. 
Furthermore, I expect fewer genes will be affected when freshly isolated PBMCs are 
compared to sister aliquots that undergo the freezing process in a rate-controlled freezer 
as compared to those that are placed inside a CoolCell device, all of which were stored in 
the freezer for 1 month before being thawed.  
 
Background Information on Biobanks 
 Biobanks are responsible for the proper biospecimen handling, i.e., collecting, 
processing, inventorying, storing and shipping of biospecimens.  As a result, Biobanks 
play a critical role in designing appropriate logistical biospecimen handling solutions that 
are necessary to answer basic science and clinical research questions that will ultimately 
improve patient care (Morente et al., 2011).  Collecting significant numbers of 
biospecimens as well as the high quality data associated with each sample involves a 
considerable effort in planning.  Advocating for and implementing Biobanks that operate 
based on scientifically based “Best Practices” would facilitate access to high quality 
biospecimens and related data for researchers. Therefore, this thesis will provide 
scientific information for establishing “Best Practices” for isolating, processing and 
cryopreserving human PBMCs using gene expression analysis.  
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Goals of Biogen’s Biobank 
 Biogen’s Biobank capabilities are evolving and the Biobank is striving to be 
“World Class” by 2017. A World-Class Biobank will help Biogen in reaching many of its 
strategic objectives. To be considered a World-Class Biobank will require focusing on 6 
key imperatives: 1.) Operate a high quality Biobank, 2.) Expand services to include 
biospecimen processing and acquisition, 3.) Perform biospecimen-related research with a 
focus on biospecimen handling, 4.) Leverage technology to provide innovative 
operational solutions to the Biobank, 5.) Automate storage and implement high-
throughput biospecimen processing and 6.) Expand and solidify information technology 
(IT) and operational systems integration across all Biobank locations. 
 
Background Information on PBMCs 
 PBMCs are mononuclear white blood cells, e.g., Monocytes, T cells, B cells, and 
NK cells. PBMCs play a crucial role in the immune system as they recognize foreign 
bodies and help the body fight infection. PBMCs are used to evaluate different in vitro 
functional and phenotypic immunological assays such as enzyme-linked immunosorbent 
spot (ELISPOT) assays, proliferation assays, flow cytometry and cytometry by time-of-
flight (CyTOF) determinations. In translational medicine, PBMCs can function as 
precursors for potential immunotherapy development and can be used for biomarker 
discovery. PBMC samples are an important biospecimen type collected by Biogen and 
are often collected, processed and cryopreserved at multiple clinical sites, which makes 
standardization a concern.  
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 Ruitenberg et al. (2006) suggests that clinical researchers usually prefer to obtain 
whole blood from patients at pre-determined time points, collect and cryopreserve 
PBMCs and perform assays at a later time or after multiple biospecimens have been 
collected in an effort to batch samples. They also suggest that cryopreserving and 
evaluating biospecimens at a central laboratory is standard practice in order to minimize 
operator, site and temporal variability as well as to enhance the precision and accuracy of 
immunoassays. Ruitenberg et al. (2006) indicated that clinical investigators usually 
employ one of two methods to collect whole blood; 1). Using a vacutainer tube, or 2). 
Using a CPT vacutainer. Using a vacutainer tube means that samples are collected and 
shipped to the central laboratory to have PBMCs isolated using a ficoll density 
centrifugation method; whereas, using a CPT vacutainer generally means that upon 
collection the CPT vacutainers are centrifuged at the collection site and then shipped to 
the central laboratory for PBMC recovery and this separation technology offers 
processing versatility (Ruitenberg et al., 2006).   
 The last decade and a half has provided great advances in the knowledge of 
programmed cell death (apoptosis), flow cytometry methods and microarray gene 
expression analysis for PBMCs (Lempicki et al., 2013; Peng et al.2007; Germann et al. 
2013). Studies taking advantage of propidium iodide viability staining used in flow 
cytometry have clearly shown that cryopreservation has a greater negative impact on 
PBMC quality than previously thought based on trypan blue cell staining (Lempicki et 
al., 2013; Peng et al.2007; Germann et al. 2013). 
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Gene Expression 
 Baechler et al. (2004) states that on a genomic scale, gene expression profiling 
has made extensive progress in identifying molecular pathways correlated with human 
malignancies as well as other various diseases. Previous studies that Baechler et al. 
(2004) investigated have largely depended upon using biopsied tissues from healthy 
volunteers and tumors from individuals affected with cancers. However, obtaining these 
types of samples can be difficult as these types of tissues are not always readily available 
for harvesting for all diseases; the procedure is invasive, uncomfortable to the patient and 
obtaining this type of material is costly (Baechler et al., 2004).  
 More recently the gene expression profiles of PBMCs were used to detect 
variations in expression patterns in healthy donors, with a goal of further characterizing 
underlying mechanisms of disease (Fan & Hegde, 2005). However, previous research has 
shown that gene expression was affected by issues related to the ex vivo handling of 
samples prior to the extraction of RNA (Baechler et al., 2004; Barnes et al. 2010; Debey 
et al.2004). 
 Whitney et al. (2003) found that experiments performed in vivo have delved into 
various facets of the physiological regulation of human gene expression programs, which 
includes identifying genes periodically expressed during various stages of the cell cycle, 
the response of human cells to different stimuli as well as the dissection of various 
signaling pathways. In a more clinical setting, gene expression profile patterns help to 
define the complexity of various biological processes associated with health as well as 
disease in vivo (Whitney et al., 2003). Gene expression profiling is helpful in predicting 
diseases as well as classifying biospecimens, determining the efficacy of drugs, toxicity 
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classification and prognosis of diseases (Fan & Hegde, 2005). Previous research has 
shown that the technical aspects of blood sampling, cell isolation, the techniques used for 
RNA isolation and various clinical aspects including length of time until data is analyzed 
and the temperature used during processing have an effect on gene expression patterns 
(Debey et al., 2004).  
 
Previous Gene Expression Research 
 All of the information contained below was summarized from the work from a single 
reference, e.g., Lempicki et al., 2013.  
Leidos Biomedical Research (formally SAIC-Frederick, Inc.) followed an IRB-
approved protocol, in which whole blood was collected from 10 healthy donors in 2005. 
The whole blood was collected in vacutainers, which contained Acid Citrate Dextrose 
(ACD). Ficoll density-centrifugation was used to isolate PBMCs; the PBMCs were then 
washed, counted and the viability was determined using a light microscope along with a 
hemocytometer and trypan blue staining. Viability, apoptosis and necrosis were also 
determined using flow cytometry with propidium iodide, 7AAD and Annexin V staining, 
respectively, as a comparison.  
 Cells for storage were frozen at 10x106 cells/ml using a cryococktail of 20% fetal 
calf serum + 7.5% dimethyl sulfoxide (DMSO) + 72.5% RPMI-1640 media. A rate-
controlled freezer was used to cool all of the PBMC-containing vials to -150°C, once 
cooled to -150°C the sample vials were stored at three different storage conditions. The 
sample vials were sorted so that vials from each donor were administered to each of three 
storage conditions. The first condition was vapor liquid nitrogen storage at -150°C. At -
!  )!
150°C, the samples were at a static storage state. The second condition mimics sample 
storage and temperature fluctuations associated with sample sorting and “sample cherry 
picking,” a routine activity in Biobanks. Thus, in the second condition the samples were 
cycled 104 times between -150°C, -80°C and back to -150oC using a rate-controlled 
freezer. The rate-controlled freezer was programmed in the following way: the starting 
temperature was -150°C; the temperature was then increased +10°C/min until the 
temperature reached -80°C; once the temperature reached -80°C it held temperature at -
80°C for 10 min; then the temperature was decreased at -30°C/min until it reached -
150°C; once the temperature reached -150°C it held temperature at -150°C for 10 
minutes.   The temperature was finally held at -150°C until the vials were transferred to 
vapor phase LN2.  The third and final condition was static storage of the PBMCs at -
80°C.  
 PBMCs were stored frozen for 14 months. After being stored for the desired 
amount of time, the samples were thawed rapidly, diluted in media, and counted using 
trypan blue exclusion for viability and cell recovery. Immediately after being counted, the 
cells were analyzed using flow cytometry for viability, apoptosis and necrosis. If it was 
determined that sufficient cells were available; an aliquot was placed in RLT lysis buffer 
for gene expression analysis.  
 Total RNA was extracted from cryopreserved PBMCs samples that were stored 
frozen for 14 months along with matching freshly isolated PBMC control samples.  
Microarray gene expression analysis was performed using the Affymetrix U133 2.0 Plus 
array in 2007 using the recommended manufacture’s protocol at that time. Differentially 
regulated genes were defined as those that had an ANOVA p<0.05 and an absolute fold 
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change greater than five.  Pathway analysis was conducted using DAVID and Ingenuity 
Pathway.  
In Figure 1.1 below, the up-regulated genes (Clusters 1) were strongly associated 
with apoptosis and the MAP Kinase, JUN Kinase and p38 stress-activated Kinase 
pathways, respectively; whereas, Cell Death and Defense Response Pathways were 
similarly associated with both Clusters 1 and 2. Overall, there were 1,367 genes (in 
clusters 1 and 2) that showed 3-fold log difference.  
 
Figure 1.1. Gene Expression Alterations by Cryopreservation Conditions. 
 
Visual summary of 1,367 differentially expressed genes following cryopreservation. The 
expressed genes from PBMC samples stored for 14 months in the 3 storage conditions are 
presented in Cluster 1 (increased expression) and Cluster 2 (decreased expression) as 
related to freshly isolated PBMCs that have an absolute FC>3.  
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All of the information contained below was summarized from the work from a single 
reference, e.g., Ruitenberg et al., 2006.  
 Many previous studies have shown that several factors have an effect on 
functional T cell responses such as shipping, storage, age, cryopreservation and thawing 
of samples. Some of the same studies suggest that immunophenotyping, proliferation and 
functional assays should only be performed on fresh samples while other studies suggest 
that using frozen PBMCs is an acceptable option for functional assays. However, it is 
crucial that PBMCs are processed and handled in such a way as to not degrade the cells 
ability to have a response to activation stimuli. It is also crucial to ensure that enough 
viable PBMCs are collected during the isolation and cryopreservation process to be able 
to perform the desired studies.  
 Based on this information, Ruitenberg et al. decided to research whether or not 
samples processed using CPT vacutainers could be used as a replacement for ficoll 
density centrifugation since separating PBMCs using ficoll density centrifugation is a 
labor-intensive process. Researchers were interested in looking at blood samples from 
HIV seropositive patients. Typically, in HIV vaccine clinical trials the blood of HIV 
seropositive patients is collected at several different study sites, then the samples are 
shipped to a central laboratory where the samples undergo PBMC isolation and 
evaluation. For this study, two sites obtained whole blood from 19 seropositive HIV 
patients in both sodium heparin CPT vacutainers and sodium heparin vacutainers. At 
each collection site, the sodium heparin CPT vacutainers were centrifuged within 2 hours 
according to the manufacturers’ specifications and inverted several times. The 
centrifuged sodium heparin CPT vacutainers and the unprocessed sodium heparin 
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vacutainers were then shipped at ambient temperature overnight to a central laboratory. 
Upon arrival the sodium heparin vacutainers were processed using ficoll density 
centrifugation and the processing of the sodium heparin CPT vacutainers was completed 
according to manufacturer’s recommendations. The collected PBMCs from both 
vacutainer types were counted, cryopreserved with cryococktail and then stored frozen. 
The PBMCs were thawed and underwent cytokine flow cytometry (CFC) assays to 
determine the antigenic stimuli of the PBMCs.  
 Ruitenberg et al. found that with fresh blood samples, samples processed with 
ficoll density centrifugation had a significantly better viability compared to sodium 
heparin CPT processed PBMCs. But with cryopreserved samples the sodium heparin 
CPT processed PBMCs had a better viability than the ficoll density centrifugation 
processed PBMCs although the difference was not significant. Between the two methods 
of processing, the fresh and cryopreserved PBMCs recoveries were not significantly 
different. It was concluded that regardless of whether fresh samples or cryopreserved 
samples are used, sodium heparin CPT vacutainers are in fact a very effective method for 
obtaining functionally active PBMCs, at least for HIV seropositive patients. Overall, 
these results revealed that PBMCs prepared by either method actually perform 
equivalently meaning that using sodium heparin CPT vacutainers to collect PBMCs from 
blood may be a viable alternative to using ficoll density centrifugation, especially when 
collecting samples at various sites and shipping them to a central processing laboratory 
location.  
All of the information contained below was summarized from the work from a single 
reference, e.g., Cosentino et al., 2007. 
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 It is commonly accepted that PBMCs are fragile and that mishandling PBMCs 
during the cryopreservation and thawing process can jeopardize their function in 
comparison to fresh PBMCs. Published data has focused on how cryopreservation has 
impacted cell death.  Specifically, ice crystal formation which is a phase change from 
liquid to crystalline solid as well as acute changes in osmolality which impacts cellular 
integrity can damage cells and decrease viable cell recovery.  Based on this, freezing 
media and cryopreservatives were engineered to assist with reducing cell death and 
sustain viability during the process of freezing and thawing. Published data suggests 
more causes of cold-induced cell death such as cellular membrane damage, dehydration, 
and the formation of reactive oxygen species (ROS), all of which can have a negative 
effect on the quality of PBMCs. It is believed that necrotic events cause hypothermia and 
cryopreservation injury to cells. A major concern seems to be that apoptosis occurs when 
PBMCs are cryopreserved; this phenomenon is known as cryopreservation-induced 
delayed-onset cell death (CIDOCD). 
 The biological phenomenon known as apoptosis, results due to the activation of a 
genetically encoded cell death-signaling program. The activation of the program 
contributes to a form of cell death, which is differentiated from necrosis by a specific set 
of morphological features including chromatin condensation, membrane blebbing, loss of 
nuclear and cell volume and lastly a characteristic patterned fragmentation of nuclear 
DNA. Apoptosis results in the regulated elimination of cells at the same time as 
minimizing tissue damage without generating inflammation. At a molecular level, a 
receptor-linked or a DNA damage-induced death signal such as p53-inducible genes are 
involved in most apoptotic pathways. Furthermore, a signal transduction pathway exists 
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which involves mitochondrial-derived factors including cytochrome c release and ROS 
and it is under the control of regulatory factors such as intracellular Ca2+ ions, balance of 
antiapoptotic Bcl-2 and pro-apoptotic Bax proteins. Activated proteases known as 
caspases & DNA endonucleases are involved in the final, common apoptosis execution 
pathway.  Cell freezing-cocktails minimize damage to cells due to ice crystal formation, 
but are not able to protect PBMCs from undergoing apoptosis caused by CIDOCD. 
CIDOCD has been reported to play a role in PBMC cryopreservation failure; however, 
there is limited understanding regarding the extent, timing and activation stressors.  
 
Conclusion  
 Overall, the gene expression results from my thesis will offer insight into 
Biogen’s goal of identifying a standardized way to process PBMCs for all of their clinical 
studies. My goal is to document that different PBMC isolation and processing procedures 
used in Biogen’s basic and clinical research projects have an effect on the gene 
expression patterns of PBMCs, which is critical when these biospecimens are used in 
biomarker discovery.  
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Chapter II 
Materials & Methods 
 
 Biogen has a volunteer donor program in which Biogen employees' donate whole 
blood for research purposes. There were 10 healthy donors that provided between 96 mLs 
– 106 mLs of whole blood for this thesis research study. Each individual donated whole 
blood approximately in equal amounts into 2 different vacutainers: sodium heparin CPT 
vacutainers and sodium heparin vacutainers. There were two cryopreservation methods 
used to viably preserve PBMCs: a CoolCell & a rate-controlled freezer, with each method 
preserving a multiple number of cryovials.  
 Each time an individual donated whole blood; the phlebotomist simultaneously 
collected both vacutainer types as required for this experiment. The whole blood was 
processed immediately after being collected and at least 4 aliquots of PBMCs were 
collected during the isolation process (please see Table 2.2 below for a summary of the 
specific steps used for the collection). RNA was isolated from the aliquots of 
biospecimens and later analyzed by gene expression to determine the specific cellular 
pathways that were affected.  
By using the two vacutainer types and the two cryopreservation procedures, it 
begins to allow Biogen to better understand how these processing variables may affect 
gene expression profiles from PBMCs that are routinely used in biomarker discovery 
research. 
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Samples Uploaded into Biogen’s Biobank’s Watson Database 
 There were a total of 3820 samples produced for this project and all of them were 
entered into the Biobank’s Watson Database so their chain of custody could be properly 
tracked. Each sample was uniquely labeled.  Below in Table 2.1, the labeling scheme 
used in this thesis is summarized so that the samples could be tracked from the collection 
of whole blood through any specific processing that was performed, aliquot size stored 
and its intended use. The standard Sample ID label format used was: GX1.247802-1000-
0.  The Sample IDs are composed of 3 parts:  Study ID, Collection Event ID and 
Sequence Number. The Study ID = GX1.  The Study ID is the first 3 alpha numerics, 
e.g., GX1, which links/identifies the samples to Graduate Experiment 1. Collection 
Event ID = 247802. The Collection Event ID has 2 pieces of information embedded in it:  
- The Donor ID is the first 4 digits 247802 that identifies the individual donating a 
specimen from Biogen’s employee donor program.   
- The last 2 digits, 247802, indicate which vacutainer type was used. 02 = sodium 
heparin CPT vacutainer; and 03 = sodium heparin vacutainer. 
The Sequence Number is the last 5 digits of the Sample ID, -1000-0, that is preceded by 
a hyphen and that groups the first 4 digits together and separates the last digit by a second 
hyphen. The Sequence Number identifies a particular specimen material type that was 
collected as the “parent” material, e.g., 1000-0 (1st 8 mL Sodium Heparin CPT 
vacutainer); whereas, e.g., 4201-1 to 4201-5 (5 cryovials of cryopreserved PBMCs at 
2x106 cells/mL in RLT). 
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Table 2.1. Sample ID Assignments and Descriptions. 
 Sample ID Description 
GX1.247802-1000-0 
-1100-0 
-1200-0 
-1300-0 
-1400-0 
-1500-0 
Sodium Heparin CPT Vacutainers #1-6 
GX1.247802-1600-0 Pooled Whole Blood in a 50 mL sterile conical tube 
GX1.247802-2000-0 & -2100-0 Whole Blood CPT in RLT Aliquot #1 & #2 
GX1.247802-2000-1 & -2100-1 RNA from Whole Blood CPT in RLT Aliquot #1 & #2 
GX1.247802-2000-2 & -2100-2 QC Aliquot of RNA from Whole Blood CPT in RLT Aliquot #1 & #2 
GX1.247802-2000-3 & -2100-3 Normalized RNA Aliquot from Whole Blood CPT in RLT Aliquot #1 &#2 for EA 
GX1.247802-3000-0 & -3100-0 Fresh PBMCs in RLT Aliquot #1 & #2 
GX1.247802-3000-1 & -3100-1 RNA from PBMCs in RLT Aliquot #1 & #2 
GX1.247802-3000-2 & -3100-2 RNA QC Aliquot PBMCs in RLT Aliquot #1 & #2 
GX1.247802-3000-3 & -3100-3 Normalized RNA Aliquot PBMCs in RLT Aliquot #1 & #2 for EA 
GX1.247802-4000-0 
-4100-0 
-4200-0 
-4300-0 
1 mL aliquot of cryopreserved PBMCs at 5x106 OR 10x106 cells/mL, 
Using a CoolCell 
GX1.247802-4001-0 to -4005-0 
-4101-0 to -4105-0 
-4201-0 to -4205-0 
-4301-0 to -4305-0 
Cryopreserved PBMCs at 2x106 cells/mL in RLT, Using a CoolCell 
GX1.247802-4001-1 to -4005-1 
-4101-1 to -4105-1 
-4201-1 to -4205-1 
-4301-1 to -4305-1 
RNA from Cryopreserved PBMCs at 2x106 cells/mL in RLT, Using a 
CoolCell 
GX1.247802-4001-2 to -4005-2 
-4101-2 to -4105-2 
-4201-2 to -4205-2 
-4301-2 to -4305-2 
QC Aliquot of RNA from Cryopreserved PBMCs at 2x106 cells/mL in 
RLT, Using a CoolCell 
GX1.247802-4001-3 to -4005-3 
-4101-3 to -4105-3 
-4201-3 to -4205-3 
-4301-3 to -4305-3 
Normalized Aliquot of RNA from Cryopreserved PBMCs at 2x106 
cells/mL in RLT for EA, Using a CoolCell 
GX1.247802-5000-0 
-5100-0 
-5200-0 
-5300-0 
1 mL aliquot of cryopreserved PBMCs at 5x106 OR 10x106 cells/mL, 
Using a Rate-Controlled Freezer 
GX1.247802-5001-0 to -5005-0 
-5101-0 to -5105-0 
-5201-0 to -5205-0 
-5301-0 to -5305-0 
Cryopreserved PBMCs at 2x106 cells/mL in RLT, Using a Rate-Controlled 
Freezer 
GX1.247802-5001-1 to -5005-1 
-5101-1 to -5105-1 
-5201-1 to -5205-1 
-5301-1 to -5305-1 
RNA from Cryopreserved PBMCs at 2x106 cells/mL in RLT, Using a 
Rate-Controlled Freezer 
GX1.247802-5001-2 to -5005-2 
-5101-2 to -5105-2 
-5201-2 to -5205-2 
-5301-2 to -5305-2 
QC Aliquot of RNA from Cryopreserved PBMCs at 2x106 cells/mL in 
RLT, Using a Rate-Controlled Freezer 
GX1.247802-5001-3 to -5005-3 
-5101-3 to -5105-3 
-5201-3 to -5205-3 
-5301-3 to -5305-3 
Normalized Aliquot of RNA from Cryopreserved PBMCs at 2x106 
cells/mL in RLT for EA, Using a Rate-Controlled Freezer 
This table illustrates a typical set of Sample IDs and the Sample Description for all of the 
samples used in this research project obtained and processed from a single donor. 
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Preparing the Biosafety Cabinet 
 The blower in the Biosafety Cabinet was turned on for 15 minutes prior to use. 
After 15 minutes had elapsed, the inside and the front air grate of the Biosafety Cabinet 
were sprayed with Citrus II disinfectant. The Citrus II was wiped away using Kim wipes. 
Next the inside of the Biosafety Cabinet was sprayed with 70% Ethanol. The 70% 
Ethanol was wiped away using Kim wipes. The Biosafety Cabinet was then ready for use. 
 
Setting the Acceleration & Deceleration Speeds on the Thermo Scientific Sorvall Legend 
XTR Centrifuge 
 The ACC/DEC key was pressed twice so that "Set deceleration” appeared on the 
display. The desired deceleration speed was selected by entering the appropriate number 
on the numeric pad. Number 0 is equivalent to off, number 1 is the slowest and number 9 
is the fastest. The entry was confirmed by pressing ENTER. The ACC/DEC key was 
pressed once so that "Set acceleration” appeared on the display. The desired acceleration 
speed was selected by entering a 9 on the numeric pad. Number 0 is equivalent to off, 
number 1 is the slowest and number 9 is the fastest. The entry was confirmed by pressing 
ENTER. 
 
Thawing Frozen Pre-Aliquoted Fetal Calf Serum (FCS) in the Water Bath 
 The water bath temperature was set at 37°C. The FCS aliquot was placed into the 
water bath for 5 minutes, within the 5 minute time interval the conical tube was inverted 
several times. After 5 minutes, the FCS aliquot was removed from the waterbath, the tube 
was sprayed with 70% ethanol and then the 70% ethanol was wiped off with a Kim wipe. 
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The FCS aliquot was inverted 10 times. If the FCS aliquot was not thawed, the above 
steps were repeated until it was thawed. Once the FCS was thawed, it was placed on wet 
ice or at 4°C until it was used. Once the FCS aliquot was thawed it was consumed that 
day, as it cannot be used at a later date and it cannot be re-frozen. 
 
Estimating the Volume in a Vacutainer 
 Using a set of vacutainer tares containing measured water in 1 mL increments 
from 1 mL to 10 mLs, the volume of blood in each vacutainer was estimated. 
 
Isolating PBMCs from Whole Blood in Sodium Heparin CPT vacutainers 
 The sodium heparin CPT vacutainers containing whole blood were stored in an 
upright position at room temperature until centrifugation. The sodium heparin CPT 
vacutainers were re-mixed by gently inverting the tubes 8 to 10 times before 
centrifugation.  
 Two aliquots of 300 µL of whole blood from each donor’s vacutainer were taken 
and each aliquot was placed into a 15 mL conical tube per vacutainer type.  The whole 
blood was centrifuged at 1400 x g for 5 minutes at 10°C. Using a 5 mL serological 
pipette, the supernatant was removed and the pellet was dislodged. The whole blood was 
washed in 5 mL of sterile PBS and centrifuged at 1400 x g for 5 minutes at 10°C. Using a 
5 mL serological pipette, the supernatant was removed and the pellet was dispersed by 
tapping the tube against the technician’s hand. Using a P-1000 pipette with a sterile 
plugged aerosol-free pipet tip, 600 µL of room temperature RLT lysis buffer were added 
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to each tube and then resuspended up pipetting up and down 20 times. The entire volume 
of each tube was placed into prelabeled cryovials and stored at –80°C.  
 The sodium heparin CPT vacutainers were centrifuged in a horizontal rotor 
(swing-out head) for 30 minutes at 1650 x g at room temperature with the acceleration 
speed set at 9 and the deceleration speed set at 2. After centrifugation, PBMCs and 
platelets were localized in a whitish layer just under the plasma layer and just above the 
CLEAR density gradient fluid layer. Being as delicate as possible, each blood tube was 
slowly inverted 5 times to homogenize the plasma and the PBMCs/platelets. Using a 5 
mL serological pipette the homogenized plasma!,-.!PBMCs/platelets from each sodium 
heparin CPT vacutainer were aspirated and pooled into a pre-labeled 50mL conical tube. 
The sodium heparin CPT vacutainers were then properly discarded. The 50 mL conical 
tube was centrifuged for 15 minutes at 300 x g at room temperature with the acceleration 
speed set at 9 and the deceleration speed set at 6. Without disturbing the PBMC pellet, a 
10 mL serological pipette was used to aspirate and discard as much plasma as possible. 
Using a 10 mL serological pipette, 10 mL of sterile RPMI-1640 were added to the 50 mL 
conical tube containing the PBMC pellet. Using the same 10 mL serological pipette, the 
PBMC pellet was resuspended by pipetting the RPMI-1640 up and down. Enough sterile 
RPMI-1640 was poured into the 50 mL conical tube to bring the total volume up to 50 
mL. The 50 mL conical tube was centrifuged for 15 minutes at 300 x g at room 
temperature with the acceleration speed set at 9 and the deceleration speed set at 6. Using 
a 10 mL serological pipette, as much supernatant as possible was aspirated & discarded 
without disturbing the cell pellet. The PBMC pellet was resuspended by using a 10 mL 
serological pipette to add 10 mL of sterile RPMI-1640 to the 50 mL conical tube 
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containing the cell pellet. Using the same 10 mL serological pipette, the PBMC pellet 
was resuspended by pipetting the RPMI-1640 up and down. Enough sterile RPMI-1640 
was poured into the 50 mL conical tube to bring the total volume up to 50 mL. The 50 
mL conical tube was centrifuged for 10 minutes at 300 x g at room temperature with the 
acceleration speed set at 9 and the deceleration speed set at 6. Using a 10 mL serological 
pipette, as much supernatant as possible was aspirated & discarded without disturbing the 
cell pellet. Three 50 mL conical tubes containing 45 mL of sterile RPMI-1640 (90%) + 5 
mL of FCS (10%) were created to use for subsequent wash & cell counting steps during 
the isolation. These 3 conical tubes were kept on wet ice until they were used. The PBMC 
cell pellet was resuspended in half of the 90% sterile RPMI-1640 + 10% FCS solution. 
Using a 5 mL serological pipette, the cell suspension was gently mixed by aspirating and 
expelling the liquid. The resuspension of the PBMC pellet was completed by adding the 
remaining half of the 90% sterile RPMI-1640 + 10% FCS solution. Using a 5 mL 
serological pipette, the PBMC suspension was gently mixed by aspirating and expelling 
the liquid. The PBMCs were then counted using a Vi-CELL. The total # of PBMCs in the 
cell suspension was calculated by using the following formula: 
Total viable PBMCs / mL (x106) x Total mL of cell suspension 
 Two aliquots of fresh PBMCs at 2x106 were taken and each aliquot was placed 
into a 15 mL conical tube.  The fresh PBMCs were centrifuged at 1400 x g for 5 minutes 
at 10°C. Using a 5 mL serological pipette, the supernatant was removed and the pellet 
was dislodged. The fresh PBMCs were washed in 5 mL of sterile PBS and centrifuged at 
1400 x g for 5 minutes at 10°C. Using a 5 mL serological pipette, the supernatant was 
removed and the pellet was dislodged. Using a P-1000 pipette with a sterile plugged 
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aerosol-free pipet tip, 600 µL of room temperature RLT lysis buffer were added to each 
tube and then resuspended by pipetting up and down 20 times. The entire volume of each 
tube was placed into prelabeled cryovials and stored at –80°C.  
 The remaining PBMC suspension was inverted 4-5 times, and using a 25 mL 
serological pipette it was approximately evenly split between two prelabeled 50 mL 
conical tubes, one tube was designated to use a Biocision CoolCell FTS30 Cell Freezing 
Container to freeze half of the remaining cryopreserved PBMCs while the other tube was 
designated to use a rate-controlled freezer to freeze the other half of the remaining 
cryopreserved PBMCs (see Cryopreservation of PBMCs section below).  
 
Isolating PBMCs from Whole Blood in Sodium Heparin Vacutainers Using Ficoll-
Density Gradients  
 Two vacutainers of whole blood containing sodium heparin were pooled into a 
sterile 50 mL conical tube. For example, if there were 2 vacutainers, the whole blood in 
both vacutainers was pooled into one 50 mL conical tube. If there were 4 vacutainers, the 
samples were pooled into two 50 mL conical tubes. 
 Two aliquots of 300 µL of whole blood were taken from each donor’s vacutainer 
and each aliquot was placed into a 15 mL conical tube per vacutainer type.  The whole 
blood was centrifuged at 1400 x g for 5 minutes at 10°C. Using a 5 mL serological 
pipette, the supernatant was removed and the pellet was dislodged. The whole blood was 
washed in 5 mL of sterile PBS and centrifuged at 1400 x g for 5 minutes at 10°C. Using a 
5 mL serological pipette, the supernatant was removed and the pellet was dislodged. 
Using a P-1000 pipette with a sterile plugged aerosol-free pipet tip, 600 µL of room 
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temperature RLT lysis buffer were added to each tube and then resuspended by pipetting 
up and down 20 times. The entire volume of each tube was placed into prelabeled 
cryovials and stored at –80°C. ! The 50 mL conical tubes containing the whole blood were centrifuged at 450 x g 
for 20 minutes with the acceleration set at 9 and the deceleration set at 9. After 
centrifugation, the plasma was separated from the cellular components, (e.g., RBCs, 
PBMCs and polymorphonuclear cells) and all of the cellular components were pelleted at 
the bottom of the tube. Without disturbing the PBMC/platelet layer, a 5 mL serological 
pipette was used to gently aspirate and discard the plasma. Enough sterile plain RPMI-
1640 media was poured into each conical tube to bring the volume up to 35 mL. The 
pelleted cells were resuspended by gently & slowly rocking the tube 5-10 times. To 
another sterile 50 mL conical tube, 13 mL of Ficoll-Paque was added. NOTE: There 
should be one 50 mL conical tube filled with Ficoll-Paque per 50 mL conical tube filled 
with pelleted cells. The cell suspension was slowly and carefully poured over the Ficoll-
Paque to prevent it from mixing with the diluted blood. A clear interface (the location 
where the Ficoll-Paque and the cell suspension met) was observed. This was repeated for 
each tube. The samples were centrifuged at 900 x g for 30 minutes with the acceleration 
set at 9 and the deceleration set at 2. The tubes were removed from the centrifuge, placed 
in a biosafety cabinet and their caps were removed.  The clear media was aspirated-off 
the top and discarded using a sterile 10 mL serological pipette except for approximately 
10 mLs of media that was directly above the PBMC/platelet layer. Using a 5 mL sterile 
serological pipette, the PBMC/platelet layer was carefully collected and placed into 
another 50 mL conical tube. NOTE: This was a 1:1 transfer meaning all of the 
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PBMC/platelet layers were NOT pooled together, each 50 mL conical tube containing a 
PBMC/platelet layer was transferred into its own 50 mL conical tube. Enough sterile 
RPMI-1640 media was added to each 50 mL conical tube containing the PBMC/platelet 
layer to bring the volume up to 50 mL. The PBMC/platelet suspension was then gently 
inverted 4-5 times. The PBMCs were pelleted by being centrifuged at 450 x g for 10 
minutes with the acceleration set at 9 and the deceleration set at 2. Using a 50 mL 
serological pipette, the supernatant was aspirated and discarded. The PBMCs were 
resuspended in 10 mL of plain sterile RPMI-1640 media and the PBMC suspension was 
gently inverted 4-5 times. Using a 10 mL serological pipet, ALL of the washed PBMCs 
were pooled into a single 50 mL conical tube. The now empty 50 mL conical tubes, 
which had previously contained the washed PBMCs, were rinsed with 5 mL of plain 
sterile RPMI-1640 media. The rinsed RPMI-1640 media containing any residual PBMCs 
was transferred to the single 50 mL conical tube containing that pooled PBMC 
suspensions. Enough sterile plain RPMI-1640 media was poured into the single 50 mL 
conical tube to bring the volume up to 50 mL. The PBMC suspension was gently inverted 
4-5 times. The PBMC suspensions were centrifuged at 450 x g for 10 minutes with the 
acceleration set at 9 and the deceleration set at 9. A 10 mL serological pipet was used to 
aspirate and discard the supernatant. Three 50 mL conical tubes containing 45 mL of 
sterile RPMI-1640 (90%) + 5mL of FCS (10%) were created to use for subsequent wash 
and cell counting steps during the isolation. The three 50 mL conical tubes were kept on 
wet ice until they were used. Each donor’s PBMCs were separately resuspended in half 
of 90% sterile RPMI-1640 + 10% FCS. Using a 5 mL serological pipette, the cell 
suspension was gently mixed by aspirating and expelling the liquid 4 – 5 times. The 
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volume of each PBMC resuspension was brought up to 50 mL with the 90% sterile 
RPMI-1640 + 10% FCS solution. Using a 5mL serological pipette, the PBMC suspension 
was gently mixed by aspirating and expelling the liquid. The PBMCs were then counted 
using a Vi-CELL. The total # of PBMCs in the cell suspension was calculated by using 
the following formula: 
Total viable cells / mL (x106) x Total mL of cell suspension 
 Two aliquots of fresh PBMCs at 2x106 were taken and each aliquot was placed 
into a 15 mL conical tube.  The fresh PBMCs were centrifuged at 1400 x g for 5 minutes 
at 10°C. Using a 5 mL serological pipette, the supernatant was removed and the pellet 
was dispersed by gently tapping the tube in the palm of the technician’s hand. The 
PBMCs were washed in 5 mL of sterile PBS and centrifuged at 1400 x g for 5 minutes at 
10°C. Using a 5 mL serological pipette, the supernatant was removed and the pellet was 
dispersed. Using a P-1000 pipette with a sterile plugged aerosol-free pipet tip, 600 µL of 
room temperature RLT lysis buffer were added to each tube and then resuspended by 
pipetting up and down 20 times. The entire volume of each tube was placed into 
prelabeled cryovials and stored at –80°C.  
 The remaining PBMC suspension was inverted 4-5 times, and using a 25 mL 
serological pipette it was approximately evenly split between two prelabeled 50 mL 
conical tubes, one tube was designated to use a Biocision CoolCell FTS30 Cell Freezing 
Container to freeze the cryopreserved PBMCs while the other tube was designated to use 
a rate-controlled freezer to freeze the cryopreserved PBMCs (see Cryopreservation of 
PBMCs section below). 
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Cryopreservation of PBMCs 
 All of the 50 mL conical tubes that had remaining PBMCs isolated from the 
sodium heparin CPT vacutainers and the sodium heparin vacutainers were centrifuged at 
300 x g for 10 minutes at room temperature with the acceleration speed set at 9 and the 
deceleration speed set at 6. Without disturbing the PBMC pellet, a 10 mL serological 
pipette was used to aspirate and discard as much supernatant as possible. From this point 
on the remainder of protocol was performed on WET ICE. The conical tubes containing 
the PBMC pellets were placed on wet ice while the cryococktail solution was prepared. 
The following 3 calculations were used to determine the amount of cryococktail solution 
(72.5% RPMI-1640 + 20% FCS + 7.5% DMSO) required to achieve a desired cell 
concentration of EITHER 5x106 OR 10x106 cells/mL depending on the cell count: 
1). Total amount in mL of cryococktail solution needed for 10x106 cells/mL =  
Total # of cells in cell suspension / 5x106 cells/mL or 10x106 cells/mL 
2). Total amount in mL of RPMI-1640 (72.5%) in cryococktail =!!
Total amount in mL of cryococktail solution needed for 5x106 or 10x106  
cells/mL x 0.725 
3). Total amount in mL of FCS (20%) in cryococktail =!!
Total amount in mL of cryococktail solution needed for 5x106 or 10x106  
cells/mL x 0.20 
4). Total amount in mL of DMSO (7.5%) in cryococktail =!!
Total amount in mL of cryococktail solution needed for 5x106 or 10x106  
cells/mL x 0.075 
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 The rate-controlled freezer was turned on to ensure it was running for about 30 
minutes before it was used.  This allowed the probe temperature in the rate-controlled 
freezer to reach +4oC before the cryovials with the PBMCs that are to be cryopreserved 
were placed inside.  
 For each conical tube containing PBMCs to be frozen using a CoolCell, the 
cryococktail required to achieve a desired cell concentration of either 5x106 cells/mL or 
10x106 cells/mL was made in a 50 mL conical tube. A 5 mL serological pipette was used 
to resuspend the PBMC pellet in half of the desired volume of cryococktail solution to 
achieve the desired cell concentration of either 5x106 cells/mL or 10x106 cells/mL.  
Using the same 5 mL serological pipette, the PBMC suspension was mixed by aspirating 
and expelling the liquid 5 times. For complete resuspension, a 5 mL serological pipette 
was used to add in the remaining half of the desired volume of cryococktail solution, 
which achieved a cell concentration of either 5x106 cells/mL or 10x106 cells/mL.  
 From the cryopreserved PBMCs at either 5x106 cells/mL or 10x106 cells/mL, 1 
mL of cell suspension was aliquotted into as many prelabeled sterile cryovials as 
possible. The vials were quickly transferred from wet ice into a Biocision CoolCell 
FTS30 Cell Freezing Container. Any empty slot (not filled by a PBMC-containing 
sample) within the Biocision CoolCell FTS30 Cell Freezing Container were filled with 2 
mL CoolCell Filler Vials to ensure a controlled freezing rate of -1!/minute. The 
Biocision CoolCell FTS30 Cell Freezing Container containing samples was then placed 
into a -70"C freezer overnight. The next day, the frozen cryovials containing PBMCs 
residing in the Biocision CoolCell FTS30 Cell Freezing Container were transferred to a -
150"C freezer.  
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 For each conical tube containing cells designated to be frozen using a rate-
controlled freezer, the cryococktail required to achieve a desired cell concentration of 
either 5x106 cells/mL or 10x106 cells/mL was made in a 50 mL conical tube. A 5 mL 
serological pipette was used to resuspend the cell pellet in half of the desired volume of 
cryococktail solution to achieve the desired cell concentration of either 5x106 cells/mL or 
10x106 cells/mL.  Using the same 5 mL serological pipette, the cell suspension was 
mixed by aspirating and expelling the liquid 5 times. For complete resuspension, a 5 mL 
serological pipette was used to add in the remaining half of the desired volume of 
cryococktail solution, which achieved a cell concentration of either 5x106 cells/mL or 
10x106 cells/mL.  
 From the cryopreserved PBMCs at either 5x106 cells/mL or 10x106 cells/mL, 1 
mL of cell suspension was aliquotted into as many prelabeled sterile cryovials as 
possible. The vials were quickly transferred from wet ice to a rate-controlled freezer.  
 Immediately after loading the PBMC-containing cryovials in the rate-controlled 
freezer, the operator selected the program titled “Biogen Biobank (BBK) Run” and then 
clicked on “Run.”   
BBK Run:  
• Hold at +4oC 
• Ramp 1oC/min until sample = -4oC 
• Ramp 25oC/min until chamber = -40oC 
• Ramp 15oC/min until chamber = -12oC 
• Ramp 1oC/min until chamber  = -40oC 
• Ramp 10oC/min until chamber = -150oC 
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• Hold at -150oC until samples are retrieved to move to long-term storage 
 At the completion of the rate-controlled freezing cycle, the cryovials were 
removed from the rate-controlled freezer and quickly transported in a Styrofoam 
container that had liquid nitrogen-soaked absorbent pads to maintain a <-150oC 
temperature until the PBMC samples were stored long-term in a -150oC freezer.     
 
Thawing Cryopreserved PBMCs 
 Thawing cryopreserved PBMCs was done using the following rapid thaw 
procedure: The water temperature in a water bath was at 37ºC before beginning this 
process. Using a serological pipette, 10 mL of CHILLED RPMI-1640 media plus 10% 
FCS were aliquoted into a 15 mL conical tube. When thawing more than one vial, each 
vial was transferred to a separate 15 mL conical tube. A maximum of 4 vials were taken 
through this procedure at one time. Immediately after removing the vials from the freezer, 
they were placed in a container of dry ice so all of the vials were covered in dry ice for 
transportation to the laboratory where the 37ºC water bath was located.  The frozen vials 
were placed in the 37ºC water bath. The water was not allowed to reach the collar of the 
vial to prevent contamination. Just before the last few ice crystals melted in the vial, the 
vial was removed from the water bath. A kimwipe was sprayed with 70% ethanol & the 
vial was wiped off with it before being opened. A 2 mL serological pipette was used to 
draw up the cells and media from the cryovial and then to transfer the cells and media into 
the 15 mL conical tube containing the RPMI-1640 media + 10% FCS. Using the same 
serological pipette, 1.5 mL of the cell suspension were aspirated from the top of the 15 mL 
conical tube, used to rinse the vial and transferred back into the 15 mL conical tube. The 
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cells were gently pipetted up and down twice to mix. The cells were pelleted by being 
centrifuged at 500 x g for 10 minutes at 10°C with the acceleration set at max and the 
deceleration set at max. Using a 5 mL serological pipette, the supernatant was removed. 
The cells were gently resuspended in 10 mL of CHILLED RPMI-1640 media + 10% FCS. 
The PBMCs were pelleted by being centrifuged at 500 x g for 10 minutes at 10°C with the 
acceleration set at 9 and the deceleration set at 9. Using a 5 mL serological pipette, the 
supernatant was removed. The PBMCs were gently resuspended in 5 mL of CHILLED 
RPMI 1640 media + 10% FCS. The PBMCs where then counted on a Vi-CELL. 
 Up to 5 aliquots of cells at 2x106 were pipetted into their own 15 mL conical 
tube.  The conical tubes were then centrifuged at 1400 x g for 5 minutes at 10°C. Using a 
5 mL serological pipette, the supernatant was removed and the pellet was dispersed by 
gently tapping on the side of the conical tube with a finger. The cells were washed in 5 mL 
of sterile PBS and centrifuged at 1400 x g for 5 minutes at 10°C. Using a 5 mL serological 
pipette, the supernatant was removed and the pellet was dispersed by gently tapping on the 
side of the conical tube using a finger. Using a P-1000 pipette with a sterile plugged 
aerosol-free pipet tip, 600 µL of CHILLED RLT lysis buffer were added to each tube and 
then resuspended up pipetting up and down 20 times. The entire volume of each tube was 
placed into separate prelabeled cryovials and stored at –80°C.  
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Table 2.2. Summary of Whole Blood & PBMC Aliquots Taken During Whole Blood 
Processing.  
Aliquots Taken 
at the 
Indicated 
Processing 
Steps 
PBMC Isolation from 
Whole Blood 
Collected in Sodium Heparin Vacutainers 
PBMC Isolation from 
Whole Blood 
Collected in Sodium Heparin CPT Vacutainers 
Aliquot # 1 
(x2) 
Pool Whole Blood Containing the Same Preservative into 50 mL 
conical tubes 
Collect Whole Blood from 
Pool & Add to RLT Lysis Buffer 
Collect Whole Blood from 
Sodium Heparin CPT Vacutainers & Add to RLT Lysis 
Buffer 
 
Centrifuge 450 x g for 20 minutes at RT 
Discard supernatant 
Dilute Pelleted Cells with 35 mLs of RPMI-1640 media & Gently 
Rock 5-10 times 
Centrifuge Sodium Heparin CPT Vacutainers 
at 1,650 x g for 30 minutes (No Brake) 
 
Pour Diluted Cells over 13 mL Ficoll 
Centrifuge at 900 x g for 30 minutes at RT   
 
Discard Supernatant 
Transfer PBMC layer to 50 mL conical tube  
 
Gently Mix PBMCs & Plasma 
Collect & Pool into a 50 mL conical tube Centrifuge PBMCs 
& Plasma at 300 x g 15 minutes at RT 
  
Aspirate & Discard Plasma 
Add 10mLs RPMI-1640 media to 
Pelleted PBMCs  & Resuspend 
 
QS RPMI-1640 media to 50 mLs  (Wash #1) 
Centrifuge PBMCs at 450 x g for 10 minutes at RT  
Discard Supernatant 
Resuspend PBMCs in 10 mLs 
RPMI-1640 media 
QS RPMI-1640 media to 50 mLs (Wash #1) 
Centrifuge PBMCs at 300 x g for 15 minutes at RT 
Discard Supernatant 
Resuspend PBMCs in 10 mLs 
RPMI-1640 media 
 
Pool ALL Washed Cells into ONE 50 mL Conical Tube 
Rinse the Now Empty Conical Tubes with 5 mL of RPMI-1640 & 
Transfer the RPMI-1640 into the 50 mL Conical Tube Containing 
PBMCs  
 
 
QS RPMI-1640 media to 50 mLs (Wash #2) 
Centrifuge PBMCs at 450 x g for 10 minutes at RT 
Discard Supernatant 
Resuspend PBMCs in 90% RPMI-1640 & 10% FCS 
 
QS RPMI-1640 media to 50 mLs (Wash #2) 
Centrifuge PBMCs at 300 x g for 10 minutes at RT 
Discard Supernatant 
Resuspend PBMCs in 90% RPMI-1640 & 10% FCS 
 
Aliquot # 2 
(x2) 
Count PBMCs & 
Add 2x106 PBMCs to RLT Lysis Buffer 
Count PBMCs & 
Add 2x106 PBMCs to RLT Lysis Buffer 
 
Centrifuge PBMCs at 300 x g for 10 minutes at RT  
Discard Supernatant 
Place PBMCs on Wet Ice 
Add appropriate amount of Cryococktail for 5x106or 10x106 
PBMCs  
Freeze 
Centrifuge PBMCs at 300 x g for 10 minutes at RT  
Discard Supernatant 
Place PBMCs on Wet Ice 
Add appropriate amount of Cryococktail for 5x106or 10x106 
PBMCs  
Freeze  
Aliquot #3 (x2) 
After 1 month, Thaw Samples 
Count PBMCs 
Add 2x106 PBMCs to RLT Lysis Buffer 
After 1 month, Thaw Samples 
Count PBMCs 
Add 2x106 PBMCs to RLT Lysis Buffer 
This table compares the two PBMC isolation methods used and shows at what step the 
whole blood & PBMC aliquots were collected. 
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Culturing and Harvesting Mouse Fibroblast Cells 
 Flasks of adherent mouse M2-10B4 primary stromal fibroblast cells were grown 
in RPMI-1640 + 10% FCS complete medium to ~60% confluency as observed by light 
microscopy. The complete medium was aspirated from the cell monolayer by pipet and 
discarded. The cell monolayer was briefly rinsed once with 7 mL PBS and then the PBS 
was discarded. Five mL of trypsin-EDTA was added to the cell monolayer and the cells 
were allowed to incubate in a 37"C/5% CO2 incubator for 3 minutes. Following 
incubation, the flask was tapped smartly on the hard edge of the counter to disrupt the 
trypsinized cells. Cell detachment was verified by light microscopy. The trypsinized cells 
were resuspended in 30 mL of complete medium to stop the reaction, and the whole 
volume was transferred to a 50 mL conical centrifuge tube and pelleted by centrifugation 
at 300 x g for 10 minutes at room temperature. Following centrifugation, the supernatant 
was resuspended in 10 mL of PBS. Cells were counted manually with a 1:2 dilution of 
trypan blue on a hemocytometer. When desired, aliquots of either 0.5x106 or 1x106 cells 
were made and they were placed into a 15 mL conical tube with an additional 10 mL of 
sterile PBS.   
 
Vi-CELL XR Beckman Coulter Cell Counter Operating Instructions 
 The Vi-CELL XR 2.04.004 software program opens by double clicking on the icon 
that is located on the home screen on the computer connected to the Vi-CELL.  In order 
for the program to start, the user logs in with their user name and password. The Vi-CELL 
initializes itself, which takes a few minutes. Once the status of the Vi-CELL is “Idle,” the 
Vi-CELL Concentration Control needs to be retrieved from the +4"C refrigerator. An 
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aliquot of 1.5 mL of the Vi-CELL Concentration Control is placed into a Vi-CELL sample 
cup. The sample is placed onto any position on the Vi-CELL. The Autosampler queue 
icon is selected by double clicking on it0!!! A new screen appears and the “Log In Sample” icon is selected by double clicking 
on it. In the new “Log In Sample” window that appeared, the following information for 
the Concentration Control is entered:  
• Position-Corresponding position was selected 
• Sample ID-Conc. Control_Users Initials_Date_Lot # of Conc. Control 
• Cell Type-Conc. Control 
• Dilution Factor-1 
• Date-Automatically filled in for user 
• Time- Automatically filled in for user 
 The “OK” icon is selected, and then the “Start” queue icon is selected. When the 
Concentration Control sample is finished running, the Beckman Coulter Run Results 
screen appeared. The Total cells/mL is looked at and confirmed that it was within +/- 
10% of the concentration (Total count/µL) provided by Beckman Coulter for that specific 
bottle of Concentration Control. If the Concentration Control was not within +/- 10% of 
the concentration (Total count/µL) provided by Beckman Coulter for that specific bottle 
of Concentration Control, the Concentration Control was rerun.  
 To process samples; 1mL of a PBMC suspension was added into a Vi-CELL 
sample cup, and the sample was placed onto any position on the Vi-CELL. The 
Autosampler queue icon was selected by double clicking on it.  
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 In the new screen that appeared, the “Log In Sample” icon was double clicked on. In 
the new “Log In Sample” window that appeared, the following information for the 
PBMC suspension was filled out:  
• Position-Corresponding position was selected 
• Sample ID-Vacutainer Type_Date of Extraction_Users Initials_Date Run on 
Vi-CELL 
• Cell Type-PBMC #1 
• Dilution Factor-1 
• Date-Automatically filled in for user 
• Time- Automatically filled in for user 
Once the sample was finished running, the Beckman Coulter Run Results screen 
appeared. Using the Total cells/mL, the total number of cells in the PBMC suspension 
was calculated using the following equation: 
Total # of cells in cell suspension = Total # cells/mL x106 x Total mLs of cell suspension 
 
Manually Counting Cells Using a Hemocytometer 
 In a 2.0 mL cryovial, 100 µL of cell suspension & 900 µL of Trypan Blue were 
added & then it was gently mixed by finger flicking. Using a P-20 pipette with a sterile 
plugged aerosol-free pipet tip, 10 µL of the cell suspension & trypan blue mixture were 
added into the hemocytometer. The microscope was turned on high and it was placed on 
the lowest power objective (e.g. PhL). The Field diaphragm control lever was closed and 
the hemocytometer was placed on the microscope. All of the viable PBMCs (non-viable 
cells stain blue, viable cells appear bright white with a halo around them) in each of the 
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four quadrants were manually counted. The total cell count for all four quadrants is 
approximately 100 cells. If more than 100 cells were counted, the cell suspension was 
further diluted and the cells were recounted. The total # of cells in the cell suspension 
was calculated using the following equation: 
Total # of cells in cell suspension = (Total # of cells in ALL 4 quadrants/# of quadrants) 
x constant of 10,000 cells/mL x dilution factor of trypan blue x total volume in mL of cell 
suspension 
 
RNA Extraction Protocols 
 Four RNA extraction protocols were tested while troubleshooting the DNA 
contamination issue. The kit initially used to isolate RNA from the original test samples 
did not contain a DNase treatment, which was Qiagen’s RNeasy Mini Kit without a 
DNase treatment. This procedure was compared to Qiagen’s AllPrep DNA/RNA Mini 
Kit, RNeasy Mini Kit with and without a DNase treatment and RNeasy Plus Mini Kit. 
 
Isolating RNA from Whole Blood, PBMCs & Cryopreserved PBMCs Stored in RLT 
Lysis Buffer Using Qiagen’s RNeasy Mini Kit 
 The Purification of Total RNA from Animal Cells using Spin Technology 
protocol from Qiagen’s RNeasy Mini Kit was used to isolate RNA from the whole blood, 
fresh PBMCs & cryopreserved PBMCs stored in RLT lysis buffer. If samples were 
frozen they were left on the bench to thaw for 1 hour. If samples were being DNase 
treated, the DNase stock solution was either made or if it was previously made the DNase 
was removed from the +4°C refrigerator. Using a P-1000 pipette, the DNase stock 
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solution was prepared by dissolving the lyophilized DNase I (1500 Kunitz units) in 550 
µL of RNase-free water. The DNase stock solution was then mixed gently by inverting 
the vial. The DNase stock solution was stored in the +4°C refrigerator for up to 1 month. 
Using an L-1200 XLS multi-channel pipette, each of the lysed samples was transferred 
into a QIAshredder spin column for homogenization purposes. The QIAshredder spin 
columns were then centrifuged for 2 minutes at maximum speed (21,130 x g). Using an 
L-1200 XLS multi-channel pipette, 600 µL of 70% ethanol was added to each 
homogenized lysate and using the same L-1200 XLS multi-channel pipette, the samples 
were aspirated and dispensed 5 times to mix. Using an L-1200 XLS multi-channel 
pipette, 700 µL of lysate was transferred into an RNeasy spin column and centrifuged by 
holding the short button down on the centrifuge for 20 seconds to ensure that the samples 
were centrifuged for 15 seconds at greater than or equal to 8000 x g. After centrifugation, 
the flow-through was discarded. If the sample volume exceeded 700 !l, successive 
aliquots in the same RNeasy spin column were centrifuged and the flow-through was 
discarded after each centrifugation.  
 If samples were DNase treated it was at this point and the following instructions 
were followed, if samples were not being DNase treated, the next paragraph of this 
protocol was proceeded to. Otherwise, using an L-1200 XLS multi-channel pipette, 350 
µL of Buffer RW1 were added to each RNeasy spin column. The lid was gently closed 
and the RNeasy spin columns were centrifuged for 15 seconds at greater than or equal to 
8000 x g to wash the spin column membrane. After centrifugation, the flow-through was 
discarded. Using a P-200 & a P-1000 pipette, a mastermix was created in which 10 µL of 
DNase stock solution and 70 µL Buffer RDD were added into a 1.5mL fliptop tube per 
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number of RNeasy spin columns. The DNase mixture was gently mixed by inverting the 
1.5mL fliptop tube and it was centrifuged briefly to collect residual liquid from the sides 
of the tube. Using a P-200 pipette, 80 µL of the DNase mixture were added directly to 
each RNeasy spin column membrane. The RNeasy spin columns were left on the 
benchtop to incubate for 15 minutes.  The lid was gently closed and RNeasy spin 
columns were centrifuged for 15 seconds at greater than or equal to 8000 x g to wash the 
spin column membrane. After centrifugation, the flow-through was discarded.  Using an 
L-1200 XLS multi-channel pipette, an additional 350 µL of Buffer RW1 were added to 
each RNeasy spin column. The lid was gently closed and the RNeasy spin columns were 
centrifuged for 15 seconds at greater than or equal to 8000 x g as instructed by Qiagen to 
wash the spin column membrane. This protocol was continued with the first Buffer RPE 
wash step below. 
 Using an L-1200 XLS multi-channel pipette, 700 µL of Buffer RW1 were added 
to the RNeasy spin columns. The RNeasy spin columns were centrifuged by holding the 
short button down on the centrifuge for 20 seconds to ensure that the samples were 
centrifuged for 15 seconds at greater than or equal to 8000 x g. After centrifugation, the 
flow-through was discarded.  
 Using an L-1200 XLS multi-channel pipette, 500 µL of Buffer RPE was added to 
the RNeasy spin columns. The RNeasy spin columns were centrifuged by holding the 
short button down on the centrifuge for 20 seconds to ensure that the samples were 
centrifuged for 15 seconds at greater than or equal to 8000 x g. After centrifugation, the 
flow-through was discarded. Using an L-1200 XLS multi-channel pipette, an additional 
500 µL of Buffer RPE was added to the RNeasy spin columns. The RNeasy spin columns 
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were centrifuged for 2 minutes at maximum speed (21,130 x g). After centrifugation the 
RNeasy spin columns were placed into a new 2 mL collection tube and the old collection 
tube containing the flow-through was discarded. The RNeasy spin columns were 
centrifuged for 1 minute at maximum speed (21,130 x g). The RNeasy spin columns were 
then placed into new 1.5 mL collection tubes and 30 µL of RNase-free water were added 
directly to the spin column membrane. The RNeasy spin columns were centrifuged for 1 
minute at maximum speed (21,130 x g). After centrifugation, an additional 30 µL of 
RNase-free water were added directly to the spin column membrane. The RNeasy spin 
columns were centrifuged for 1 minute at maximum speed (21,130 x g). After 
centrifugation, the samples were placed on wet ice and a manual volume check was 
performed on each sample. Lastly, a 5 µL aliquot was taken from each sample to use to 
perform quantitation at a later date. The stock samples & the 5 µL aliquots were stored at 
-80oC. 
 It is important to note that the 1st set of RNA samples were extracted using the 
RNeasy Mini Kit without a DNase treatment. Upon concluding the DNA contamination 
evaluation, it was determined that the replacement RNA samples would be extracted 
using the RNeasy Plus Mini Kit (see protocol below) since it successfully removes DNA 
with a gDNA eliminator column. 
 
Isolating RNA from PBMCs & Cryopreserved PBMCs Stored in RLT Lysis Buffer 
Using Qiagen’s AllPrep DNA/RNA Mini Kit  
 The Simultaneous Purification of Genomic DNA and Total RNA from Animal 
Cells protocol from Qiagen’s AllPrep DNA/RNA Mini Kit was used to isolate RNA from 
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the whole blood, PBMCs & cryopreserved PBMCs stored in RLT lysis buffer. Using an 
L-1200 XLS multi-channel pipette, the lysate was pipetted directly into a QIAshredder 
spin column placed inside of a 2 mL collection tube, and the spin columns were 
centrifuged for 2 minutes at maximum speed (21,130 x g). Using an L-1200 XLS multi-
channel pipette, 1 volume of 70% ethanol (600 µL) was added to the flow-through. The 
lysate/ethanol mixture was pipetted up and down using the same L-1200 XLS multi-
channel pipette. An L-1200 XLS multi-channel pipette was used to pipette 700 µL of the 
lysate/ethanol mixture into the RNeasy spin columns placed inside of 2 mL collection 
tubes. The lids were closed and the RNeasy spin columns were centrifuged by holding 
the short button down on the centrifuge for 20 seconds to ensure that the samples were 
centrifuged for 15 seconds at greater than or equal to 8000 x g and then the flow-through 
was discarded. If the sample volume exceeded 700 !l, successive aliquots in the same 
RNeasy spin column were centrifuged and the flow-through was discarded after each 
centrifugation. Using an L-1200 XLS multi-channel pipette, 700 µL Buffer RW1 were 
added to each RNeasy spin column. The lids were closed and the RNeasy spin columns 
were centrifuged by holding the short button down on the centrifuge for 20 seconds to 
ensure that the samples were centrifuged for 15 seconds at greater than or equal to 8000 x 
g and then the flow-through was discarded. Using an L-1200 XLS multi-channel pipette, 
500 µL Buffer RPE were added to each RNeasy spin column. The lids were closed and 
the RNeasy spin columns were centrifuged by holding the short button down on the 
centrifuge for 20 seconds to ensure that the samples were centrifuged for 15 seconds at 
greater than or equal to 8000 x g and then the flow-through was discarded. An additional 
500 µL Buffer RPE were added to each RNeasy spin column using an L-1200 XLS 
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multi-channel pipette. The lids were closed and the RNeasy spin columns were 
centrifuged for 2 minutes at maximum speed (21,130 x g). The RNeasy spin columns 
were placed inside of new 2 mL collection tubes and the old collection tubes containing 
the flow-through were discarded. The RNeasy spin columns were centrifuged for 1 
minute at maximum speed (21,130 x g). The RNeasy spin columns were placed inside of 
new 1.5 mL collection tubes and using a P-200 pipette, 30–50 µL of RNase-free water 
were added directly to the spin column membrane. The lids were closed the RNeasy spin 
columns were centrifuged for 1 minute at maximum speed (21,130 x g) to elute the RNA. 
Using a P-200 pipette, an additional 30–50 µL of RNase-free water were added to the 
RNeasy spin columns. The lids were closed the RNeasy spin columns were centrifuged 
for 1 minute at maximum speed (21,130 x g) to elute the RNA. After centrifugation, the 
samples were placed on wet ice and a manual volume check was performed on each 
sample. Lastly, a 5 µL aliquot was taken from each sample to use to perform quantitation 
at a later date. The stock samples & the 5 µL aliquots were stored at -80oC. 
 
Isolating RNA from PBMCs & Cryopreserved PBMCs Stored in RLT Lysis Buffer 
Using Qiagen’s RNeasy Plus Mini Kit 
 The Purification of Total RNA from Animal Cells protocol from Qiagen’s 
RNeasy Plus Mini Kit was used to isolate RNA from the PBMCs & cryopreserved 
PBMCs stored in RLT lysis buffer. Using an L-1200 XLS multi-channel pipette, the 
lysate was pipetted directly into a QIAshredder spin column placed inside of a 2 mL 
collection tube, and the spin columns were centrifuged for 2 minutes at maximum speed 
(21,130 x g). The homogenized lysate was then transferred to a gDNA Eliminator spin 
!  %+!
column placed in a 2 mL collection tube. The gDNA Eliminator Columns were then 
centrifuged for 30 seconds at maximum speed (21,130 x g). The columns were discarded 
and the flow-through was saved. Using an L-1200 XLS multi-channel pipette, 1 volume 
(600 µL) of 70% ethanol was added to the flow-through, and the lysate mixture was 
pipetted up and down several times to mix it. Up to 700 µL of the sample were 
transferred using an L-1200 XLS multi-channel pipette into an RNeasy spin column 
placed in a 2 mL collection tube. The lids were closed and the RNeasy spin columns were 
centrifuged by holding the short button down on the centrifuge for 20 seconds to ensure 
that the samples were centrifuged for 15 seconds at greater than or equal to 8000 x g and 
then the flow-through was discarded. If the sample volume exceeded 700 !l, successive 
aliquots in the same RNeasy spin column were centrifuged and the flow-through was 
discarded after each centrifugation. Using an L-1200 XLS multi-channel pipette, 700 µL 
Buffer RW1 were added to the RNeasy spin column. The lids were closed and the 
RNeasy spin columns were centrifuged by holding the short button down on the 
centrifuge for 20 seconds to ensure that the samples were centrifuged for 15 seconds at 
greater than or equal to 8000 x g and then the flow-through was discarded. Using an L-
1200 XLS multi-channel pipette, 500 µL Buffer RPE were added to the RNeasy spin 
column. The lids were closed and the RNeasy spin columns were centrifuged by holding 
the short button down on the centrifuge for 20 seconds to ensure that the samples were 
centrifuged for 15 seconds at greater than or equal to 8000 x g and then the flow-through 
was discarded. Using an L-1200 XLS multi-channel pipette, an additional 500 µL Buffer 
RPE were added to the RNeasy spin column. The lids were closed and the RNeasy spin 
columns were centrifuged for 2 minutes at maximum speed (21,130 x g).  The RNeasy 
!  %"!
spin columns were placed inside a new 2 mL collection tube; the old collection tube 
containing the flow-through was discarded. The RNeasy spin columns were centrifuged 
for 1 minute at maximum speed (21,130 x g). The RNeasy spin columns were placed 
inside of new 1.5 mL collection tube and using a P-200 pipette, 30–50 µL of RNase-free 
water were added directly to the spin column membrane. The lids were closed the 
RNeasy spin columns were centrifuged for 1 minute at maximum speed (21,130 x g) to 
elute the RNA. Using a P-200 pipette, an additional 30–50 µL of RNase-free water were 
added to the RNeasy spin columns. The lids were closed and the RNeasy spin columns 
were centrifuged for 1 minute at maximum speed (21,130 x g) to elute the RNA. After 
centrifugation, the samples were placed on wet ice and a manual volume check was 
performed on each sample. Lastly, a 5 µL aliquot was taken from each sample to use to 
perform quantitation at a later date. The stock samples & the 5 µL aliquots were stored at 
-80oC. 
 
Post-RNA Extraction DNase Treatment 
 A TURBO DNA-free Kit was used to remove DNA from the RNA after the 
extraction process. A 0.1 volume of 10x TURBO DNase Buffer and 1 !L TURBO 
DNase were added to each tube of RNA. The tubes were mixed gently by finger flicking 
each tube 2-3 times. The samples were then incubated at 37°C for 30 minutes. A 0.1 
volume of the resuspended DNase Inactivation Reagent was added to each sample and 
then gently mixed by finger flicking each tube 2-3 times. The samples were then 
incubated for 5 minutes at room temperature, during the incubation period the samples 
were mixed occasionally by finger flicking each tube 2–3 times to disperse the DNase 
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Inactivation Reagent. The samples were then centrifuged at 10,000 " g for 1.5 minutes 
then the RNA was transferred to a new pre-labeled tube via a pipette for storage at -80oC. 
 
Running DropPlate 96 S Plates on the Trinean DropSense 96 to Obtain a Concentration 
 Samples were placed on wet ice and allowed to thaw for 30 minutes. The 
appropriate number of DropPlate 96 S Plates were removed from their packaging. The 
following wells were used as blanks on plates; A1, A6, H8, H12, therefore 2 µL of 
RNase-free water were pipetted into those wells. Next 2 µL of sample were pipetted into 
an empty well; this step was repeated for all samples. The DropPlate 96 S Plates were run 
on the Trinean DropSense 96 using the appropriate program for unlabeled RNA samples. 
 
Running RNA Nano Chips on Agilent Bioanalyzer to Obtain a RIN Score  
 Unopened RNA ladder was stored at -20°C, prepared ladder aliquots were stored 
at -70°C & all other reagents & reagent mixes were kept at 4°C when not in use to avoid 
poor results caused by reagent decomposition. The next few paragraphs detail how to set 
up the chip priming station, prepare the reagents needed to run the chips, how to load and 
run chips on the Bioanalyzer. 
Replacing the syringe. The old syringe was unscrewed from the lid of the chip priming 
station. The old syringe was released from the clip and it was discarded. A new sterile 
syringe was removed from its packaging and it was inserted into the clip. Next the 
syringe was slid into the hole of the luer lock adapter and tightly screwed onto the chip 
priming station.  
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Adjusting the base plate. The latch on the chip priming station was pulled in order to 
open the chip priming station. Using a screwdriver, the screw located on the underside of 
the base plate was opened. The base plate was lifted, reinserted into position C and the 
screw was retightened.  
Adjusting the syringe clip. The lever of the clip was released and slid up to the top 
position. 
Preparing the RNA ladder. The ladder was removed from the -20°C freezer and it was 
placed on ice to thaw. Once thawed, it was spun down quickly and placed into an RNase-
free vial. It was then heat denatured by being placed on a thermocycler set to 70°C for 2 
minutes. Once denatured, the ladder was immediately placed on wet ice. Using a P-10 
pipette, 5 µL aliquots were placed into 0.5 mL RNase-free vials. The aliquots of ladder 
not being used immediately were frozen at -70°C. The ladder being used immediately 
was placed on wet ice. 
Preparing the gel.  The gel was allowed to equilibrate to room temperature for 30 
minutes. Using a P-1000 pipette, 550 µL of RNA gel matrix were pipetted into a spin 
column. The spin column was then centrifuged at 1500 x g for 10 minutes at room 
temperature. Using a P-200 pipette, 60 µL of the gel were aliquoted into 0.5 mL RNase-
free microcentrifuge tubes. The filtered gel not being used immediately was stored at 4°C 
and consumed within 4 weeks. The filtered gel being used immediately was kept at room 
temperature. 
Preparing the gel-dye mix. The RNA dye concentrate was allowed to equilibrate to room 
temperature for 30 minutes. The RNA dye concentrate was vortexed for 10 seconds and 
spun down quickly. Next 1 µL of RNA dye concentrate was added into the 65 µL filtered 
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gel aliquot. The solution was vortexed well. Then it was centrifuged at 13,000 x g for 10 
minutes at room temperature. The prepared gel-dye mixture was used within 1 day. 
Loading the gel-dye mix. A new RNA chip was placed on the chip priming station. Using 
a P-10 pipette, 9 µL of gel-dye mix were placed in the well-marked with a black circle 
containing a white letter G in it. The plunger was positioned at 1 mL and then the chip 
priming station was closed. The plunger was pushed down until it was held by the clip. 
After exactly 30 seconds the clip was released. After 5 seconds, the plunger was slowly 
pulled back to the 1 mL position. The chip priming station was opened and 9 µL of gel-
dye mix were placed in the wells marked with a black letter G.   
Loading the Marker. Using a P-10 pipette, 5 µL of RNA marker were pipetted into all 12 
sample wells as well as the ladder well (this well was marked with a picture of a ladder).  
Loading the Ladder & Samples. Using a P-10 pipette, 1 µL of prepared ladder was 
pipetted into the ladder well (this well was marked with a picture of a ladder). Up to 12 
RNA samples were thawed on wet ice and using a P-10 pipette, 1 µL of each sample was 
aliquoted into 1 of 12 sample wells. Using a P-10 pipette, 1 µL of RNA marker was 
placed in any unused sample wells. The chip was then placed horizontally in the IKA 
vortexer and it was vortexed at 2400 rpm for 1 minute. The chip was then run in the 
Agilent 2100 Bioanalyzer instrument within 5 minutes of being vortexed using the 
Eukaryote Total RNA Nano Series II assay. 
 
Sample Labeling, Hybridization and Scanning  
 Sample labeling and hybridization were carried out using the NuGEN Ovation 
Biotin systems as described in the NuGEN Ovation Biotin system for 96 well plates 
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(version 5). Washing, staining and scanning of the hybridized arrays was completed as 
described in the Eukaryotic Target Preparation protocol in the Affymetrix expression 
analysis technical manual (702064 rev 2) for GeneChip cartridge arrays using the 
GeneChip Array Station. In summary, 20 ng of PaxGene purified total RNA was 
annealed with 2 !L “first strand primer mix” (A1) at 65°C for 5 minutes and then it was 
chilled on ice. The annealed template was incubated at 48°C for 60 minutes with 6 !L of 
first strand master mix (A2 and A3) and then it was chilled to 4°C. To the completed first 
strand reaction, 10 !L of second strand master mix (B1 and B2) were added and the 
reaction was incubated at 37°C for 30 minutes, 75°C for 15 minutes, and then it was 
cooled to 4°C. To amplify the cDNA, 120 !L of SPIA master mix were added to the 20 
!L of completed second strand reaction and the reaction was incubated at 48°C for 60 
minutes. The amplified cDNA was purified using the 96 well dye terminator removal kit 
according to the manufacturer’s recommendations. To fragment the purified and 
amplified cDNA, 5 !L of fragmentation buffer (F1) and enzyme mix (F2) were added to 
25 !L of the amplified cDNA and the reaction was incubated at 50°C for 30 minutes and 
then chilled to 4°C. Biotin labeling of the fragmented cDNA was completed by the 
addition of 5 !L biotin labeling buffer (F3) and 2.5 !L of labeling enzyme mix (F4) 
followed by an incubation at 50°C for 30 minutes and then it was cooled to 4°C. The 
fragmented and labeled cDNA was then purified using the 96 well dye terminator 
removal kit according to the manufacturer’s recommendations. 3 !g of fragmented 
labeled cDNA was resuspended in 300 µL 1X hybridization buffer containing 100 mM 
MES, 1 M [Na+], 20 mM EDTA, 0.01% Tween 20, 0.5 mg/mL Aceylated BSA, 0.1 
mg/mL herring sperm DNA, control oligo B2, and control transcripts bioB 1.5 pM, bioC 
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5 pM, bioD 25 pM, and cre 100 pM, and hybridized to Human Genome U133 plus 2.0 
GeneChip probe arrays according to manufacturer’s protocol. The hybridized GeneChip 
probe arrays were washed and stained using Streptavidin-Phycoerythrinin and amplified 
with biotinylated anti-streptavidin GeneChip Fluidics Station 400 using an antibody 
amplification protocol. The GeneChip probe arrays were scanned using GeneArray 
Scanner 3000.   
 
Quality Control of Gene Expression Data 
            Affymetrix scans were subject to quality control (QC) measures.  These tests 
included a visual inspection of the distribution of raw signal intensities and an assessment 
of RNA degradation, relative log expression (RLE), and normalized unscaled standard 
error (NUSE).  All sample scans passed these QC metrics and were included in the 
analysis.    
            The 60 CEL files were subjected to GC-content-based Robust Multi-array 
Average (GCRMA) normalization (version 2.20.0) (Irizarry, et al., 2003) & (Li & Hung 
Wong, 2001). Expression levels were log (base 2) transformed.  Probe sets that exhibited 
an average normalized intensity > 4 across all samples and coefficient of variation > 10% 
were used in a Principal Component Analysis (PCA); there were 4,824 such probe 
sets.  PCA results indicated two main groups of samples accounting for 28% of the data 
set variation in the first principal component.  This variation was not due to the following 
data features:  Donor ID, Freezing Device, or Vacutainer Type. 
            Careful inspection showed that the variation was based on whether the samples 
were from aliquot series “-1” (DNase treated post extraction) versus “-3” (DNase treated 
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during extraction and post extraction). It was confirmed that these groups of samples 
differed based on the number of times that the DNase treatment was performed.  There 
were 32 DNA contaminated samples that had been DNase treated only once after 
extraction and the 28 replacement samples that had been DNase treated during the 
extraction process and after the extraction process. 
            The Combat Tool from Bioconductor’s SVA software packages was used to 
correct for this technical artefact in the data (Leek, et al.). After Combat correction, 4,173 
probe sets exhibited an average normalized intensity > 4 across all samples and a 
coefficient of variation > 10%.  PCA on this set of normalized intensities did not show 
any clear, appreciable separation between the samples, artefact or otherwise.  After the 
combat correction, there were no longer two main groups of samples in the PCA results 
and there wasn’t any segregation based on vacutainer type or freezing device. 
To identify genes that change due to freezing method or the type of vacutainer, a 
linear modeling approach was used to fit gene expression levels (Combat-corrected, log2 
transformed) according to defined groups of samples and Bayesian posterior error 
analysis as implemented by Smyth (Bioconductor library limma, version 3.4.5) (Smyth, 
2004). The following 7 Contrasts were calculated: 
1.) Freshly isolated PBMCs collected in sodium heparin vacutainers vs Freshly isolated 
PBMCs collected in sodium heparin CPT vacutainers 
2.) Freshly isolated PBMCs collected in sodium heparin vacutainers vs Thawed PBMCs 
collected in sodium heparin vacutainers and cryopreserved in a CoolCell device  
3.) Freshly isolated PBMCs collected in sodium heparin vacutainers vs Thawed PBMCs 
collected in sodium heparin vacutainers and cryopreserved in a rate-controlled freezer 
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4.) Freshly isolated PBMCs collected in sodium heparin CPT vacutainers vs Thawed 
PBMCs collected in sodium heparin CPT vacutainers and cryopreserved in a CoolCell 
device 
5.) Freshly isolated PBMCs collected in sodium heparin CPT vacutainers vs Thawed 
PBMCs collected in sodium heparin CPT vacutainers and cryopreserved in a rate-
controlled freezer 
6.) Thawed PBMCs collected in sodium heparin vacutainers and cryopreserved in a 
CoolCell device vs Thawed PBMCs collected in sodium heparin vacutainers and 
cryopreserved in a rate-controlled freezer 
7.) Thawed PBMCs collected in sodium heparin CPT vacutainers and cryopreserved in a 
CoolCell device vs Thawed PBMCs collected in sodium heparin CPT vacutainers and 
cryopreserved in a rate-controlled freezer 
 Probe sets that exhibited a log-odds score (lods) greater than zero, absolute fold 
change >1.5, and average normalized intensity >4 were considered significantly 
different.  All calculations and analyses were carried out using R (version 2.11.1) and 
Bioconductor computational tools (Gentleman, et.al., 2005). As a sanity check, the data 
was also analyzed using only the “-3” aliquots and without any Combat correction.  This 
approach was possible since there was an even distribution of sample representation 
across the “-1” and “-3” samples.  There was a high amount of agreement between the 
two analysis approaches of using all samples versus just one set of aliquots. 
!!
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Chapter III 
Results 
 
Whole Blood Collection and PBMC Isolation Yields  
Between 96.5 mLs to 107.5 mLs of whole blood were collected in two different 
vacutainers from 10 healthy donors (5 males and 5 females) that participated in Biogen’s 
IRB-reviewed employee biospecimen donor program. The donors were of various 
ethnicities and were between 29 and 55 years of age.  Both types of vacutainers that were 
used contained sodium heparin.  One vacutainer was the standard sodium heparin 
vacutainer made by Becton Dickinson (BD); whereas, the second vacutainer also 
manufactured by BD, contained sodium heparin and also a cell separation medium inside 
the vacutainer, this vacutainer was called a Cell Preparation Tube (CPT).  Before the 
PBMCs were isolated, a representative whole blood aliquot was obtained from each 
vacutainer type and placed into RLT lysis buffer.  This was done in an attempt to obtain a 
cellular sample that was as close to PBMCs in vivo as possible. 
PBMCs were isolated from both types of vacutainers.  Ficoll-density 
centrifugation was used to isolate PBMCs from the whole blood from the 6 sodium 
heparin vacutainers from each donor.  Whereas, PBMCs were isolated directly from the 6 
sodium heparin CPT vacutainers from each donor following centrifugation of the whole 
blood due to the cell separation medium and then the PBMCs were pooled to make a 
single sample.  Once the PBMCs were isolated, they were counted using the Vi-CELL. 
The total PBMC yield per donor from the whole blood was between 18.62x106 – 
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84.28x106 PBMCs per vacutainer type as presented in Table 3.1.  Eight of the donors (4 
males and 4 females) had less blood collected in the Sodium Heparin CPT vacutainers 
but more PBMCs were isolated from these vacutainers than the Sodium Heparin 
vacutainers. 
 
Table 3.1. PBMC Yield from Whole Blood Collected by Donor. 
Subject Age Race Gender Vacutainer Type Total Volume of all 6 Vacutainers (mL) 
Total 
PBMC 
Count 
Concentration of 
Frozen PBMCs 
(cells/mL) 
2252 52 White Male 
Sodium Heparin CPT  48 37.73x106 5x106 
Sodium Heparin  55.5 22.05x106 10x106 
2253 38 White Male 
Sodium Heparin CPT 48.5 55.86x106 10x106 
Sodium Heparin  53 53.90x106 10x106 
2254 35 Asian Male 
Sodium Heparin CPT 46 57.33x106 10x106 
Sodium Heparin 50.5 46.06x106 10x106 
2392 29 White Male 
Sodium Heparin CPT 49 34.79x106 10x106 
Sodium Heparin 57 31.36x106 10x106 
2398 37 Hispanic Male 
Sodium Heparin CPT 46 43.61x106 10x106 
Sodium Heparin 55.5 62.72x106 10x106 
2400 31 White Female 
Sodium Heparin CPT 48 69.09x106 10x106 
Sodium Heparin 55.5 45.08x106 10x106 
2402 39 Black Female 
Sodium Heparin CPT 50 33.32x106 10x106 
Sodium Heparin 55 42.63x106 10x106 
2407 55 White Female 
Sodium Heparin CPT 49.5 70.56x106 10x106 
Sodium Heparin 56 59.29x106 10x106 
2409 47 Hispanic Female 
Sodium Heparin CPT 47.5 84.28x106 10x106 
Sodium Heparin 57.5 51.45x106 10x106 
2478 34 White Female 
Sodium Heparin CPT 47.5 43.12x106 10x106 
Sodium Heparin 57.5 18.62x106 5x106 
This table shows the yield of PBMCs based on the amount of whole blood obtained from 
each donor by vacutainer type. It also shows the metadata associated with each donor. 
 
PBMC Aliquot Designation and Cryopreservation 
From each donor, one 2x106 aliquot of freshly isolated PBMCs (non-frozen) was 
immediately added to RLT lysis buffer, the remaining cell suspension was split in half 
and each half was cryopreserved into aliquots of either 5x106 or 10x106 
PBMCs/ml/cryovial, depending on the total number of cells available. One set of aliquots 
!  &"!
was frozen using a CoolCell device while the second was frozen using a rate-controlled 
freezer. Regardless of the freezing methods, the cryopreserved PBMCs were stored 
frozen for 1 month in a -150°C mechanical freezer, then one aliquot from each freezing 
method was thawed, counted, aliquoted into 2x106 PBMCs and placed into RLT lysis 
buffer. Cell recovery post thaw is presented in Table 3.2 for the PBMCs that were 
cryopreserved by the 2 freezing devices.  Cell recovery varied greatly between donors 
and samples. The cell recovery ranged between 11.25% and 100% with a majority of the 
samples recovering less than half of the number of PBMCs that were cryopreserved 
based on the Vi-CELL counts. 
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Table 3.2. Summary of Donor IDs, Vacutainer Types, Custom IDs, Cell Counts & RIN 
Scores. 
Subject Vacutainer Type Custom IDs Total Cell Count at Time of Freezing 
Total Cell Count at 
Time of Thawing First RIN Score Second RIN Score 
2252 
Sodium Heparin CPT GX1.225202-3000-3 2x106 N/A 9.4 8.3 
Sodium Heparin CPT GX1.225202-4101-1 10x106 10x106 2.6 8.3 
Sodium Heparin CPT GX1.225202-5001-3 10x106 3.68x106 7.6 8.3 
Sodium Heparin GX1.225203-3000-3 2x106 N/A 6.9 8.3 
Sodium Heparin GX1.225203-4001-3 5x106 1.92x106 8.5 8.3 
Sodium Heparin GX1.225203-5001-3 5x106 1.98x106 9.7 8.3 
2253 
Sodium Heparin CPT GX1.225302-3000-3 2x106 N/A 6.9 8.3 
Sodium Heparin CPT GX1.225302-4001-3 10x106 4.68x106 8.5 8.3 
Sodium Heparin CPT GX1.225302-5101-1 10x106 6.75x106 7 8.3 
Sodium Heparin GX1.225303-3000-3 2x106 N/A 8.4 8.3 
Sodium Heparin GX1.225303-4001-3 10x106 4.545x106 6.4 8.3 
Sodium Heparin GX1.225303-5001-3 10x106 4.165x106 7.9 8.3 
2254 
Sodium Heparin CPT GX1.225402-3000-3 2x106 N/A 7.9 8.3 
Sodium Heparin CPT GX1.225402-4001-3 10x106 4.725x106 8.5 8.3 
Sodium Heparin CPT GX1.225402-5001-3 10x106 5.715x106 8 8.3 
Sodium Heparin GX1.225403-3000-3 2x106 N/A 7.8 8.3 
Sodium Heparin GX1.225403-4101-1 10x106 4x106 8.5 8.3 
Sodium Heparin GX1.225403-5001-3 10x106 4x106 6.6 8.3 
2392 
Sodium Heparin CPT GX1.239202-3000-3 2x106 N/A 9.7 8.3 
Sodium Heparin CPT GX1.239202-4001-3 10x106 4.23x106 5.9 8.3 
Sodium Heparin CPT GX1.239202-5001-3 10x106 3.51x106 8.5 8.3 
Sodium Heparin GX1.239203-3100-1 2x106 N/A 6.8 8.3 
Sodium Heparin GX1.239203-4001-3 10x106 4x106 8 8.3 
Sodium Heparin GX1.239203-5101-1 10x106 3.42x106 6.6 8.3 
2398 
Sodium Heparin CPT GX1.239802-3100-1 2x106 N/A 7.6 8.3 
Sodium Heparin CPT GX1.239802-4101-1 10x106 4.275x106 7.9 8.3 
Sodium Heparin CPT GX1.239802-5101-1 10x106 5.13x106 10 8.3 
Sodium Heparin GX1.239803-3100-1 2x106 N/A 8.6 8.3 
Sodium Heparin GX1.239803-4001-3 10x106 3.96x106 7.1 8.3 
Sodium Heparin GX1.239803-5101-1 10x106 4.365x106 7.1 8.3 
2400 
Sodium Heparin CPT GX1.240002-3000-3 2x106 N/A 7 8.3 
Sodium Heparin CPT GX1.240002-4101-1 10x106 3.285x106 7.9 8.3 
Sodium Heparin CPT GX1.240002-5001-3 10x106 3.69x106 5.4 8.3 
Sodium Heparin GX1.240003-3100-1 2x106 N/A 6.7 8.3 
Sodium Heparin GX1.240003-4001-3 10x106 3.69x106 5.2 8.3 
Sodium Heparin GX1.240003-5001-3 10x106 2.815x106 5.9 8.3 
2402 
Sodium Heparin CPT GX1.240202-3100-1 2x106 N/A 4.2 8.3 
Sodium Heparin CPT GX1.240202-4001-3 10x106 4.5x106 8.7 8.3 
Sodium Heparin CPT GX1.240202-5001-3 10x106 2.915x106 7.2 8.3 
Sodium Heparin GX1.240203-3100-1 2x106 N/A 4.7 8.3 
Sodium Heparin GX1.240203-4101-1 10x106 1.125x106 3.6 8.3 
Sodium Heparin GX1.240203-5101-1 10x106 2.7x106 5.5 8.3 
2407 
Sodium Heparin CPT GX1.240702-3100-1 2x106 N/A 5.2 8.3 
Sodium Heparin CPT GX1.240702-4001-3 10x106 3.105x106 5.2 8.3 
Sodium Heparin CPT GX1.240702-5101-1 10x106 3.015x106 4.6 8.3 
Sodium Heparin GX1.240703-3100-1 2x106 N/A 5.7 8.3 
Sodium Heparin GX1.240703-4001-3 10x106 2.655x106 6.4 8.3 
Sodium Heparin GX1.240703-5101-1 10x106 2.79x106 4.9 8.3 
2409 
Sodium Heparin CPT GX1.240902-3100-1 2x106 N/A 2.3 8.3 
Sodium Heparin CPT GX1.240902-4101-1 10x106 3.375x106 4 8.3 
Sodium Heparin CPT GX1.240902-5101-1 10x106 3.15x106 6.9 8.3 
Sodium Heparin GX1.240903-3000-3 2x106 N/A 5.4 8.3 
Sodium Heparin GX1.240903-4001-3 10x106 4.815x106 6.1 8.3 
Sodium Heparin GX1.240903-5101-1 10x106 4.50x106 4.7 8.3 
2478 
Sodium Heparin CPT GX1.247802-3100-1 2x106 N/A 4.2 8.3 
Sodium Heparin CPT GX1.247802-4101-1 10x106 2.0x106 6 8.3 
Sodium Heparin CPT GX1.247802-5101-1 10x106 2.79x106 6.3 8.3 
Sodium Heparin GX1.247803-3100-1 2x106 N/A 3.8 8.3 
Sodium Heparin GX1.247803-4001-3 5x106 1.665x106 7.9 8.3 
Sodium Heparin GX1.247803-5001-3 5x106 1.8x106 5 8.3 
This table shows in detail the 10 donors that were used, the two different vacutainer 
types, the custom ids of each sample, the cell count at the time the samples were 
cryopreserved and frozen, the cell count when the cryopreserved samples were thawed 
and counted, and the 2 RIN scores that were received during the two Bioanalyzer runs. 
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RNA Integrity Number (RIN) Score Quantification and Evaluation   
 After the various PBMC aliquots were placed into the RLT lysis buffer, RNA was 
isolated from the lysed PBMCs using the RNeasy Mini Kit. In order for the RNA to be 
run on the gene expression arrays, a RIN score of at least 7 was required. To ensure the 
RNA was of high quality, two rounds of quantitation were performed because in the first 
round of RIN evaluation only 45% (27/60) of the samples had a RIN >7, so samples were 
evaluated a second time in order to confirm these results. Likewise when the second 
round of RIN evaluation was performed, only 45% of the PBMC samples had a RIN >7 
but for the most part, the samples in the first round of quantitation with a RIN >7 were 
not the same samples in the second round of quantitation with the RIN >7. Also there 
were considerable differences in the actual RIN score from when the sample was first 
tested till it was tested again.  This lack of consistency as shown in Table 3.2 required 
further evaluation before the samples could be microarrayed.  
 
Determining the Appropriate RNA Extraction Method and a Faulty Bioanalyzer 
To explain the discrepancy in the two RIN scores, the possibility of DNA 
contamination of the RNA was considered. It is commonly known that DNA 
contamination can artificially inflate a RIN score and also cause the scoring to be 
inconsistent between evaluations.  Originally when the 60 PBMC samples had their RNA 
extracted, the RNeasy Mini Kit was used.  However, this kit did not have a DNase 
treatment step included in the process, which was thought to be the reason for the 
inconsistent and low RIN scores. Therefore, the mouse fibroblast cell line, M2-10B4, was 
expanded in culture.  Mouse fibroblast cells were used since it is easy to extract high 
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quality RNA from them and it helped to eliminate human donor RNA recovery 
variability. Mouse fibroblast cells were harvested and four aliquots of 1x106 mouse 
fibroblast cells were washed with PBS and placed into RLT lysis buffer.  Each aliquot of 
mouse fibroblast cells had their RNA extracted using one of the following 4 
commercially available RNA extraction kits: AllPrep DNA/RNA Mini Kit, RNeasy Mini 
Kit without a DNase Treatment, RNeasy Mini Kit with a DNase Treatment & RNeasy 
Plus Mini Kit.  The RNA was quantitated and their RIN score was determined on the 
Biobank’s Bioanalyzer.  All 4 RNA extraction methods produced a significant amount of 
RNA from 1x106 mouse fibroblast cells. However only the samples extracted from the 
RNeasy Mini Kit and RNeasy Plus Mini Kit produced samples that had 
electropherograms which produced quantifiable RIN scores.  Both of these samples had a 
RIN score of 10 (electropherograms not shown).  The RNA samples from the other 2 kits 
generated unreadable electropherograms, hence not producing a RIN score.  The results 
can be seen in Table 3.3. 
 
Table 3.3. RNA Extraction Method Comparison. 
Sample 
RNA  
Extraction  
Method 
RNA  
Concentration 
(ng/ul) 
RIN Score 
 
Chip # 
Mouse 
Cell Line 
All-Prep 311.81 Unreadable 1 
RNeasy Mini DNase 551.94 Unreadable 1 
RNeasy Mini 450.59 10 2 
RNeasy Plus Mini 487.47 10 2 
This table shows the RNA extraction method used, the RNA concentration, the RIN score 
& the Chip # the sample was run on for the mouse cell line.  
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Since the Biobank Bioanalyzer was not able to consistently determine a RIN score 
for most of the samples tested, a second Bioanalyzer was needed, so one was located, in 
the Molecular Biology Laboratory. Whole blood was collected in three sodium heparin 
vacutainers from a healthy volunteer that participated in the Biogen biospecimen donor 
program.  The PBMCs were isolated by ficoll-density gradient, counted and then 1, 2, 4 
and 10x106 PBMCs were added to separate aliquots of RLT lysis buffer. These 4 PBMC 
samples were extracted using the RNeasy Plus Mini Kit and quantitated on the Trinean. 
The RNA concentration for the 4 concentrations of the PBMC was fairly linear.  The 
RNA samples were evaluated on both Bioanalyzers.  As Table 3.4 shows, the Biobank 
Bioanalyzer was not able to provide a RIN score for the 4 samples but the Molecular 
Biology Laboratory’s Bioanalyzer was able to for all samples.   
 
Table 3.4. RNA Concentration and Bioanalyzer RIN Comparison. 
 
Human PBMC Number 
RNA Concentration 
(ng/ul) 
Biobank’s 
Bioanalyzer 
Molecular Lab’s 
Bioanalyzer 
1 x 106 14.76 Unreadable 5.70 
2 x 106 27.53 Unreadable 8.80 
4 x 106 51.55 Unreadable 9.90 
10 x 106 154.41 Unreadable 10 
This table shows the concentration & RIN scores from the Biobank’s & Molecular Lab’s 
Bioanalyzer for Human PBMC samples.  
 
 
Third RIN Score Evaluation 
Based on the above results, all of the original 60 PBMC samples were treated 
using DNase (post-extraction) to eliminate the DNA contamination issue, the samples 
then had their RIN scores calculated for a third and final time using the Molecular 
Biology Laboratory’s Bioanalyzer.  Table 3.5 shows the final RIN scores for all 60 
!  &'!
PBMC samples being >7, which allows for the samples to qualify for microarray 
analysis. 
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Table 3.5. Results of the Post Extraction DNase Treatment. 
 
 
Subject 
Vacutainer Type Custom IDs 
Total Cell 
Count at Time 
of Freezing 
Total Cell 
Count at Time 
of Thawing 
First RIN 
Score 
Second RIN 
Score 
Final RIN 
Score 
2252 
Sodium Heparin CPT GX1.225202-3000-3 2x106 N/A 9.4 8.3 9.4 
Sodium Heparin CPT GX1.225202-4101-1 10x106 10x106 2.6 2.7 9.7 
Sodium Heparin CPT GX1.225202-5001-3 10x106 3.68x106 7.6 7.8 9.3 
Sodium Heparin Vacutainer GX1.225203-3000-3 2x106 N/A 6.9 3.4 9.6 
Sodium Heparin Vacutainer GX1.225203-4001-3 5x106 1.92x106 8.5 7.4 9.1 
Sodium Heparin Vacutainer GX1.225203-5001-3 5x106 1.98x106 9.7 9.2 9.5 
2253 
Sodium Heparin CPT GX1.225302-3000-3 2x106 N/A 6.9 5.4 9.1 
Sodium Heparin CPT GX1.225302-4001-3 10x106 4.68x106 8.5 8.6 9.1 
Sodium Heparin CPT GX1.225302-5101-1 10x106 6.75x106 7.0 2.9 9.8 
Sodium Heparin Vacutainer GX1.225303-3000-3 2x106 N/A 8.4 6.9 9.9 
Sodium Heparin Vacutainer GX1.225303-4001-3 10x106 4.545x106 6.4 9.4 9.0 
Sodium Heparin Vacutainer GX1.225303-5001-3 10x106 4.165x106 7.9 9.1 9.3 
2254 
Sodium Heparin CPT GX1.225402-3000-3 2x106 N/A 7.9 5.1 9.3 
Sodium Heparin CPT GX1.225402-4001-3 10x106 4.725x106 8.5 7.5 8.8 
Sodium Heparin CPT GX1.225402-5001-3 10x106 5.715x106 8.0 9.1 9.1 
Sodium Heparin Vacutainer GX1.225403-3000-3 2x106 N/A 7.8 5.6 9.4 
Sodium Heparin Vacutainer GX1.225403-4101-1 10x106 4x106 8.5 2.3 9.1 
Sodium Heparin Vacutainer GX1.225403-5001-3 10x106 4x106 6.6 8.6 9.0 
2392 
Sodium Heparin CPT GX1.239202-3000-3 2x106 N/A 9.7 8.1 9.8 
Sodium Heparin CPT GX1.239202-4001-3 10x106 4.23x106 5.9 10.0 7.6 
Sodium Heparin CPT GX1.239202-5001-3 10x106 3.51x106 8.5 7.2 8.9 
Sodium Heparin Vacutainer GX1.239203-3100-1 2x106 N/A 6.8 3.3 9.8 
Sodium Heparin Vacutainer GX1.239203-4001-3 10x106 4x106 8.0 9.5 8.8 
Sodium Heparin Vacutainer GX1.239203-5101-1 10x106 3.42x106 6.6 6.9 9.3 
2398 
Sodium Heparin CPT GX1.239802-3100-1 2x106 N/A 7.6 4.2 8.4 
Sodium Heparin CPT GX1.239802-4101-1 10x106 4.275x106 7.9 3.4 9.4 
Sodium Heparin CPT GX1.239802-5101-1 10x106 5.13x106 10.0 3.9 9.8 
Sodium Heparin Vacutainer GX1.239803-3100-1 2x106 N/A 8.6 6.9 9.9 
Sodium Heparin Vacutainer GX1.239803-4001-3 10x106 3.96x106 7.1 9.7 8.6 
Sodium Heparin Vacutainer GX1.239803-5101-1 10x106 4.365x106 7.1 3.5 9.5 
2400 
Sodium Heparin CPT GX1.240002-3000-3 2x106 N/A 7.0 7.3 8.9 
Sodium Heparin CPT GX1.240002-4101-1 10x106 3.285x106 7.9 4.1 8.6 
Sodium Heparin CPT GX1.240002-5001-3 10x106 3.69x106 5.4 9.5 9.0 
Sodium Heparin Vacutainer GX1.240003-3100-1 2x106 N/A 6.7 5.2 8.5 
Sodium Heparin Vacutainer GX1.240003-4001-3 10x106 3.69x106 5.2 7.0 9.2 
Sodium Heparin Vacutainer GX1.240003-5001-3 10x106 2.815x106 5.9 9.2 9.3 
2402 
Sodium Heparin CPT GX1.240202-3100-1 2x106 N/A 4.2 3.0 9.9 
Sodium Heparin CPT GX1.240202-4001-3 10x106 4.5x106 8.7 8.8 9.2 
Sodium Heparin CPT GX1.240202-5001-3 10x106 2.915x106 7.2 8.9 9.4 
Sodium Heparin Vacutainer GX1.240203-3100-1 2x106 N/A 4.7 3.0 10.0 
Sodium Heparin Vacutainer GX1.240203-4101-1 10x106 1.125x106 3.6 3.1 7.4 
Sodium Heparin Vacutainer GX1.240203-5101-1 10x106 2.7x106 5.5 4.0 9.8 
2407 
Sodium Heparin CPT GX1.240702-3100-1 2x106 N/A 5.2 3.3 9.2 
Sodium Heparin CPT GX1.240702-4001-3 10x106 3.105x106 5.2 9.4 8.9 
Sodium Heparin CPT GX1.240702-5101-1 10x106 3.015x106 4.6 5.0 8.9 
Sodium Heparin Vacutainer GX1.240703-3100-1 2x106 N/A 5.7 1.4 9.2 
Sodium Heparin Vacutainer GX1.240703-4001-3 10x106 2.655x106 6.4 9.7 8.8 
Sodium Heparin Vacutainer GX1.240703-5101-1 10x106 2.79x106 4.9 6.5 9.4 
2409 
Sodium Heparin CPT GX1.240902-3100-1 2x106 N/A 2.3 3.7 10.0 
Sodium Heparin CPT GX1.240902-4101-1 10x106 3.375x106 4.0 5.2 8.6 
Sodium Heparin CPT GX1.240902-5101-1 10x106 3.15x106 6.9 4.5 9.4 
Sodium Heparin Vacutainer GX1.240903-3000-3 2x106 N/A 5.4 8.3 9.5 
Sodium Heparin Vacutainer GX1.240903-4001-3 10x106 4.815x106 6.1 9.3 8.9 
Sodium Heparin Vacutainer GX1.240903-5101-1 10x106 4.50x106 4.7 3.2 9.7 
2478 
Sodium Heparin CPT GX1.247802-3100-1 2x106 N/A 4.2 4.7 10.0 
Sodium Heparin CPT GX1.247802-4101-1 10x106 2.0x106 6.0 3.3 8.9 
Sodium Heparin CPT GX1.247802-5101-1 10x106 2.79x106 6.3 3.8 9.3 
Sodium Heparin Vacutainer GX1.247803-3100-1 2x106 N/A 3.8 3.0 8.8 
Sodium Heparin Vacutainer GX1.247803-4001-3 5x106 1.665x106 7.9 7.2 9.3 
Sodium Heparin Vacutainer GX1.247803-5001-3 5x106 1.8x106 5.0 7.2 9.0 
The column titled Final RIN Score shows the RIN score of each sample after the post 
extraction DNase treatment. 
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Analysis of Gene Expression Contrasts  
 There were 7 Contrasts focused on when analyzing the gene expression data.  The 
7 Contrasts are presented in Table 3.6, which also provides the number of Differentially 
Expressed Genes (DEGs) for each Contrast and a table designation that provides the Affy 
ID, Gene Name, Gene Title and Fold Change.  
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Table 3.6. Differentially Expressed Genes (DEGs) Present in Each Contrast. 
Contrast 
Number Contrast Description 
Number 
of DEGs 
List of 
Identified 
DEGs 
Located 
In: 
1 
Freshly isolated PBMCs collected in SH vacutainers  
vs  
Freshly isolated PBMCs collected in SH CPT vacutainers 
21 Table 3.7 
        
2 
Freshly isolated PBMCs collected in SH vacutainers  
vs  
Thawed PBMCs collected in SH vacutainers and 
cryopreserved in a CoolCell device 
50 Table 3.8 
3 
Freshly isolated PBMCs collected in SH vacutainers  
vs  
Thawed PBMCs collected in SH vacutainers and 
cryopreserved in a Rate-Controlled Freezer 
23 Table 3.9 
        
4 
Freshly isolated PBMCs collected in SH CPT vacutainers  
vs  
Thawed PBMCs collected in SH CPT vacutainers and 
cryopreserved in a CoolCell device 
48 Table 3.10 
5 
Freshly isolated PBMCs collected in SH CPT vacutainers  
vs  
Thawed PBMCs collected in SH CPT vacutainers and 
cryopreserved in a Rate-Controlled Freezer 
29 Table 3.11 
        
6 
Thawed PBMCs collected in SH vacutainers and 
cryopreserved in a CoolCell device  
vs  
Thawed PBMCs collected in SH vacutainers and 
cryopreserved in a Rate-Controlled Freezer 
0 N/A 
        
7 
Thawed PBMCs collected in SH CPT vacutainers and 
cryopreserved in a CoolCell device  
vs  
Thawed PBMCs collected in SH CPT vacutainers and 
cryopreserved in a Rate-Controlled Freezer 
0 N/A 
*SH=Sodium Heparin. This table shows all 7 Contrasts and the number of DEGs present 
in each Contrast. 
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The first Contrast was between the RNA extracted from PBMCs isolated from the 
whole blood collected in sodium heparin vacutainers from the 10 healthy donors and the 
RNA extracted from the PBMCs isolated from the whole blood collected in sodium 
heparin CPT vacutainers from the same 10 donors.  As shown in Table 3.6, there were 21 
DEGs identified between the PBMCs isolated from these 2 vacutainer types. Table 3.7 
lists the 21 DEGs present in Contrast #1. 
 
Table 3.7. List of 21 DEGs for Contrast #1. 
Freshly isolated PBMCs collected in SH vacutainers  
vs  
Freshly isolated PBMCs collected in SH CPT vacutainers 
Affy Id Gene Name Gene Title Fold Change 
1554443_s_at BEST1 bestrophin 1 -4.88 
1554676_at SRGN serglycin -6.97 
201041_s_at DUSP1 dual specificity phosphatase 1 -2.81 
201464_x_at JUN jun proto-oncogene -2.31 
201465_s_at JUN jun proto-oncogene -9.49 
201466_s_at JUN jun proto-oncogene -3.74 
201502_s_at NFKBIA 
nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha -2.81 
201531_at ZFP36 ZFP36 ring finger protein -1.75 
201631_s_at IER3 immediate early response 3 -2.78 
201694_s_at EGR1 early growth response 1 -3.61 
205114_s_at 
CCL3 /// CCL3L1 /// CCL3L3 /// 
LOC101060267 
chemokine (C-C motif) ligand 3 /// chemokine (C-C motif) 
ligand 3-like 1 /// chemokine (C-C motif) ligand 3-like 3 /// c-
C motif chemokine 3-like -8.31 
207113_s_at TNF tumor necrosis factor -10.30 
209189_at FOS FBJ murine osteosarcoma viral oncogene homolog -7.31 
209774_x_at CXCL2 chemokine (C-X-C motif) ligand 2 -36.63 
213281_at JUN jun proto-oncogene -5.54 
213524_s_at G0S2 G0/G1switch 2 -10.48 
223218_s_at NFKBIZ 
nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, zeta -1.89 
227404_s_at EGR1 early growth response 1 -3.14 
235102_x_at 
SNORD3A /// SNORD3B-1 /// 
SNORD3B-2 /// SNORD3C /// 
SNORD3D 
small nucleolar RNA, C/D box 3A /// small nucleolar RNA, 
C/D box 3B-1 /// small nucleolar RNA, C/D box 3B-2 /// 
small nucleolar RNA, C/D box 3C /// small nucleolar RNA, 
C/D box 3D -56.35 
236399_at 
OTTHUMG00000038014 /// RP11-
443B7.1 NULL /// NULL -17.49 
238893_at LINC00936 long intergenic non-protein coding RNA 936 -2.67 
This table lists the 21 DEGs for Contrast #1, by the Affy ID, Gene Name, Gene Title & 
Fold Change. 
 
 
The second Contrast was between freshly isolated PBMCs collected in sodium 
heparin vacutainers and thawed PBMCs (also isolated from sodium heparin vacutainers) 
that had been cryopreserved in a CoolCell device.  As presented in Table 3.6, there were 
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50 DEGs that were identified as being effected by cryopreserving the PBMCs in a 
CoolCell device, storing the PBMCs for 1 month at -150oC and then thawing the PBMCs 
for analysis by microarray.  Table 3.8 lists the 50 DEGs present in Contrast #2. 
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Table 3.8. List of 50 DEGs for Contrast #2. 
Freshly isolated PBMCs collected in SH vacutainers  
vs  
Thawed PBMCs collected in SH vacutainers and cryopreserved in a CoolCell device 
Affy Id Gene Name Gene Title Fold Change 
1554892_a_at MS4A3 membrane-spanning 4-domains, subfamily A, member 3 (hematopoietic cell-specific) -127.04 
200784_s_at LRP1 low density lipoprotein receptor-related protein 1 2.06 
202018_s_at LTF lactotransferrin -462.45 
203691_at PI3 peptidase inhibitor 3, skin-derived -105.29 
204018_x_at HBA1 /// HBA2 hemoglobin, alpha 1 /// hemoglobin, alpha 2 -629.09 
204419_x_at HBG1 /// HBG2 hemoglobin, gamma A /// hemoglobin, gamma G -213.15 
204505_s_at DMTN dematin actin binding protein -5.64 
204848_x_at HBG1 /// HBG2 hemoglobin, gamma A /// hemoglobin, gamma G -315.99 
205033_s_at DEFA1 /// DEFA1B /// DEFA3 defensin, alpha 1 /// defensin, alpha 1B /// defensin, alpha 3, neutrophil-specific -3276.89 
205513_at TCN1 transcobalamin I (vitamin B12 binding protein, R binder family) -154.81 
205592_at SLC4A1 solute carrier family 4, anion exchanger, member 1 (erythrocyte membrane protein band 3, Diego blood group) -53.72 
205624_at CPA3 carboxypeptidase A3 (mast cell) -58.47 
205857_at SLC18A2 solute carrier family 18 (vesicular monoamine), member 2 -2.39 
206207_at CLC Charcot-Leyden crystal galectin -1939.19 
206676_at CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 -730.19 
206834_at HBD hemoglobin, delta -53.09 
207269_at DEFA4 defensin, alpha 4, corticostatin -256.22 
208304_at CCR3 chemokine (C-C motif) receptor 3 -87.55 
209116_x_at HBB hemoglobin, beta -86.28 
209369_at ANXA3 annexin A3 -24.81 
209395_at CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) -68.34 
209458_x_at HBA1 /// HBA2 hemoglobin, alpha 1 /// hemoglobin, alpha 2 -689.3 
209710_at GATA2 GATA binding protein 2 -21.44 
210244_at CAMP cathelicidin antimicrobial peptide -11.92 
210254_at MS4A3 membrane-spanning 4-domains, subfamily A, member 3 (hematopoietic cell-specific) -340.42 
210517_s_at AKAP12 A kinase (PRKA) anchor protein 12 -86.4 
211696_x_at HBB hemoglobin, beta -39.11 
211699_x_at HBA1 /// HBA2 hemoglobin, alpha 1 /// hemoglobin, alpha 2 -531 
211745_x_at HBA1 /// HBA2 hemoglobin, alpha 1 /// hemoglobin, alpha 2 -426.8 
212182_at 
LOC100996752 /// 
LOC101060261 /// NUDT4 /// 
NUDT4P1 
uncharacterized LOC100996752 /// uncharacterized LOC101060261 /// nudix 
(nucleoside diphosphate linked moiety X)-type motif 4 /// nudix (nucleoside 
diphosphate linked moiety X)-type motif 4 pseudogene 1 
-1.61 
212531_at LCN2 lipocalin 2 -178.8 
212768_s_at OLFM4 olfactomedin 4 -113.17 
213515_x_at HBG1 /// HBG2 hemoglobin, gamma A /// hemoglobin, gamma G -106.83 
214414_x_at HBA1 /// HBA2 hemoglobin, alpha 1 /// hemoglobin, alpha 2 -12.44 
217232_x_at HBB hemoglobin, beta -79.45 
217414_x_at HBA1 /// HBA2 hemoglobin, alpha 1 /// hemoglobin, alpha 2 -403.4 
220266_s_at KLF4 Kruppel-like factor 4 (gut) 2.92 
220751_s_at FAXDC2 fatty acid hydroxylase domain containing 2 -12.75 
223669_at HEMGN hemogen -5.48 
223670_s_at HEMGN hemogen -11.01 
227530_at AKAP12 A kinase (PRKA) anchor protein 12 -127.85 
229247_at FBLN7 fibulin 7 -2.72 
229551_x_at ZNF367 zinc finger protein 367 -1.86 
230381_at C1orf186 chromosome 1 open reading frame 186 -23.15 
230917_at OTTHUMG00000176545 /// RP11-510J16.3 NULL /// NULL 1.78 
234396_at TRAV25 /// TRAV25 T cell receptor alpha variable 25 /// NULL -6.14 
234849_at TRAV12-3 /// TRAV12-3 T cell receptor alpha variable 12-3 /// NULL -2.07 
238931_at METTL16 methyltransferase like 16 -2.08 
241015_at --- --- -3.42 
41469_at PI3 peptidase inhibitor 3, skin-derived -103.68 
This table lists the 50 DEGs for Contrast #2, by the Affy ID, Gene Name, Gene Title & 
Fold Change. 
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Contrast #3 shows PBMC samples isolated from sodium heparin vacutainers that 
were cryopreserved with a rate-controlled freezer experienced slightly less than half that 
number of DEGs (23) than PBMC samples cryopreserved with a CoolCell. Table 3.9 
shows the 23 DEGs present in Contrast #3. 
 
Table 3.9. List of 23 DEGs for Contrast #3.  
Freshly isolated PBMCs collected in SH vacutainers  
vs  
Thawed PBMCs collected in SH vacutainers and cryopreserved in a Rate-Controlled Freezer 
Affy Id Gene Name Gene Title Fold Change 
1554892_a_at MS4A3 
membrane-spanning 4-domains, subfamily A, member 3 
(hematopoietic cell-specific) -143.39 
202018_s_at LTF lactotransferrin -485.27 
203691_at PI3 peptidase inhibitor 3, skin-derived -124.87 
205033_s_at 
DEFA1 /// DEFA1B /// 
DEFA3 
defensin, alpha 1 /// defensin, alpha 1B /// defensin, alpha 3, 
neutrophil-specific -2541.46 
205513_at TCN1 transcobalamin I (vitamin B12 binding protein, R binder family) -169.94 
205624_at CPA3 carboxypeptidase A3 (mast cell) -39.28 
205857_at SLC18A2 solute carrier family 18 (vesicular monoamine), member 2 -2.48 
206207_at CLC Charcot-Leyden crystal galectin -935.47 
206676_at CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 -770.33 
207269_at DEFA4 defensin, alpha 4, corticostatin -259.65 
208304_at CCR3 chemokine (C-C motif) receptor 3 -106.92 
209369_at ANXA3 annexin A3 -31.34 
209395_at CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) -62.54 
209710_at GATA2 GATA binding protein 2 -19.54 
210244_at CAMP cathelicidin antimicrobial peptide -11.99 
210254_at MS4A3 
membrane-spanning 4-domains, subfamily A, member 3 
(hematopoietic cell-specific) -384.91 
210517_s_at AKAP12 A kinase (PRKA) anchor protein 12 -100.08 
212531_at LCN2 lipocalin 2 -107.11 
212768_s_at OLFM4 olfactomedin 4 -122.23 
223670_s_at HEMGN hemogen -12.21 
227530_at AKAP12 A kinase (PRKA) anchor protein 12 -146.52 
230381_at C1orf186 chromosome 1 open reading frame 186 -27.16 
41469_at PI3 peptidase inhibitor 3, skin-derived -122.72 
This table lists the 23 DEGs for Contrast #3, by the Affy ID, Gene Name, Gene Title & 
Fold Change. 
 
A similar DEG response was seen when sodium heparin CPT vacutainers were 
used to isolate PBMCs.  Table 3.11 shows that there were 48 DEGs affected when a 
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CoolCell (Contrast #4) was used to cryopreserve the PBMCs as compared to Table 3.12 
which shows the 29 DEGs when the rate-controlled freezer was used (Contrast #5).  
 
Table 3.10. List of 48 DEGs for Contrast #4. 
Freshly isolated PBMCs collected in SH CPT vacutainers  
vs  
Thawed PBMCs collected in SH CPT vacutainers and cryopreserved in a CoolCell device 
Affy Id Gene Name Gene Title 
Fold 
Change 
1554892_a_at MS4A3 membrane-spanning 4-domains, subfamily A, member 3 (hematopoietic cell-specific) -39.23 
202018_s_at LTF lactotransferrin -149.84 
203691_at PI3 peptidase inhibitor 3, skin-derived -26.53 
204018_x_at HBA1 /// HBA2 hemoglobin, alpha 1 /// hemoglobin, alpha 2 -280.28 
204419_x_at HBG1 /// HBG2 hemoglobin, gamma A /// hemoglobin, gamma G -103.50 
204848_x_at HBG1 /// HBG2 hemoglobin, gamma A /// hemoglobin, gamma G -138.43 
205033_s_at DEFA1 /// DEFA1B /// DEFA3 defensin, alpha 1 /// defensin, alpha 1B /// defensin, alpha 3, neutrophil-specific -403.74 
205101_at CIITA class II, major histocompatibility complex, transactivator 1.74 
205513_at TCN1 transcobalamin I (vitamin B12 binding protein, R binder family) -41.86 
205624_at CPA3 carboxypeptidase A3 (mast cell) -25.95 
206207_at CLC Charcot-Leyden crystal galectin -449.02 
206676_at CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 -161.17 
206834_at HBD hemoglobin, delta -31.96 
207269_at DEFA4 defensin, alpha 4, corticostatin -57.24 
208304_at CCR3 chemokine (C-C motif) receptor 3 -22.66 
209116_x_at HBB hemoglobin, beta -53.12 
209458_x_at HBA1 /// HBA2 hemoglobin, alpha 1 /// hemoglobin, alpha 2 -230.80 
209710_at GATA2 GATA binding protein 2 -9.46 
209721_s_at IFFO1 intermediate filament family orphan 1 1.90 
210254_at MS4A3 membrane-spanning 4-domains, subfamily A, member 3 (hematopoietic cell-specific) -143.74 
210517_s_at AKAP12 A kinase (PRKA) anchor protein 12 -19.52 
211696_x_at HBB hemoglobin, beta -24.27 
211699_x_at HBA1 /// HBA2 hemoglobin, alpha 1 /// hemoglobin, alpha 2 -228.57 
211745_x_at HBA1 /// HBA2 hemoglobin, alpha 1 /// hemoglobin, alpha 2 -150.55 
212225_at EIF1 eukaryotic translation initiation factor 1 5.68 
212531_at LCN2 lipocalin 2 -34.70 
212926_at SMC5 structural maintenance of chromosomes 5 1.78 
213515_x_at HBG1 /// HBG2 hemoglobin, gamma A /// hemoglobin, gamma G -64.76 
213596_at CASP4 caspase 4, apoptosis-related cysteine peptidase 5.90 
213939_s_at RUFY3 RUN and FYVE domain containing 3 2.17 
214414_x_at HBA1 /// HBA2 hemoglobin, alpha 1 /// hemoglobin, alpha 2 -7.82 
215540_at TRAJ45 /// TRAJ45 /// TRAV27 /// TRAV27 T cell receptor alpha joining 45 /// NULL /// T cell receptor alpha variable 27 /// NULL -5.40 
217046_s_at AGER advanced glycosylation end product-specific receptor 3.12 
217232_x_at HBB hemoglobin, beta -44.09 
217414_x_at HBA1 /// HBA2 hemoglobin, alpha 1 /// hemoglobin, alpha 2 -172.83 
220384_at NME8 NME/NM23 family member 8 2.01 
220661_s_at ZNF692 zinc finger protein 692 3.61 
221428_s_at TBL1XR1 transducin (beta)-like 1 X-linked receptor 1 -1.55 
222529_at SLC25A37 solute carrier family 25 (mitochondrial iron transporter), member 37 -5.08 
222900_at NRIP3 nuclear receptor interacting protein 3 -3.41 
225172_at CRAMP1L Crm, cramped-like (Drosophila) 1.65 
227530_at AKAP12 A kinase (PRKA) anchor protein 12 -34.44 
230381_at C1orf186 chromosome 1 open reading frame 186 -5.73 
233227_at KIAA1109 KIAA1109 2.70 
238561_s_at UTP23 UTP23, small subunit (SSU) processome component, homolog (yeast) -2.07 
241525_at LOC200772 uncharacterized LOC200772 8.47 
39249_at AQP3 aquaporin 3 (Gill blood group) -3.43 
41469_at PI3 peptidase inhibitor 3, skin-derived -21.89 
This table lists the 48 DEGs for Contrast #4, by the Affy ID, Gene Name, Gene Title & 
Fold Change. 
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Table 3.11. List of 29 DEGs for Contrast #5.  
Freshly isolated PBMCs collected in SH CPT vacutainers  
vs  
Thawed PBMCs collected in SH CPT vacutainers and cryopreserved in a Rate-Controlled Freezer 
Affy Id Gene Name Gene Title Fold Change 
1554892_a_at MS4A3 
membrane-spanning 4-domains, subfamily A, member 3 
(hematopoietic cell-specific) -59.59 
202018_s_at LTF lactotransferrin -304.22 
203691_at PI3 peptidase inhibitor 3, skin-derived -46.06 
205033_s_at 
DEFA1 /// DEFA1B /// 
DEFA3 
defensin, alpha 1 /// defensin, alpha 1B /// defensin, alpha 3, 
neutrophil-specific -1818.53 
205513_at TCN1 transcobalamin I (vitamin B12 binding protein, R binder family) -64.88 
205624_at CPA3 carboxypeptidase A3 (mast cell) -63.71 
206207_at CLC Charcot-Leyden crystal galectin -544.99 
206676_at CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 -332.05 
206851_at RNASE3 ribonuclease, RNase A family, 3 -8.99 
207269_at DEFA4 defensin, alpha 4, corticostatin -104.44 
208304_at CCR3 chemokine (C-C motif) receptor 3 -30.59 
209369_at ANXA3 annexin A3 -24.32 
209395_at CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) -36.41 
209710_at GATA2 GATA binding protein 2 -11.58 
210244_at CAMP cathelicidin antimicrobial peptide -15.53 
210254_at MS4A3 
membrane-spanning 4-domains, subfamily A, member 3 
(hematopoietic cell-specific) -185.27 
210517_s_at AKAP12 A kinase (PRKA) anchor protein 12 -28.41 
212225_at EIF1 eukaryotic translation initiation factor 1 6.10 
212531_at LCN2 lipocalin 2 -80.50 
212768_s_at OLFM4 olfactomedin 4 -40.08 
212926_at SMC5 structural maintenance of chromosomes 5 1.72 
213939_s_at RUFY3 RUN and FYVE domain containing 3 2.16 
222040_at HNRNPA1 heterogeneous nuclear ribonucleoprotein A1 4.01 
222529_at SLC25A37 solute carrier family 25 (mitochondrial iron transporter), member 37 -5.17 
222900_at NRIP3 nuclear receptor interacting protein 3 -3.22 
227530_at AKAP12 A kinase (PRKA) anchor protein 12 -49.76 
230381_at C1orf186 chromosome 1 open reading frame 186 -8.06 
233227_at KIAA1109 KIAA1109 3.40 
41469_at PI3 peptidase inhibitor 3, skin-derived -37.80 
This table lists the 29 DEGs for Contrast #5, by the Affy ID, Gene Name, Gene Title & 
Fold Change. 
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There were a total of 23 DEGs that were common between Contrast #2 and #3.  
This list is presented in Table 3.10.   
 
Table 3.12. Comparison of DEGs Between Contrasts #2 & #3. 
Comparison between Contrast #2 and Contrast #3. 
Affy Id Gene Name Gene Title 
1554892_a_a
t MS4A3 
membrane-spanning 4-domains, subfamily A, member 3 (hematopoietic cell-
specific) 
202018_s_at LTF lactotransferrin 
203691_at PI3 peptidase inhibitor 3, skin-derived 
205033_s_at 
DEFA1 /// DEFA1B /// 
DEFA3 defensin, alpha 1 /// defensin, alpha 1B /// defensin, alpha 3, neutrophil-specific 
205513_at TCN1 transcobalamin I (vitamin B12 binding protein, R binder family) 
205624_at CPA3 carboxypeptidase A3 (mast cell) 
205857_at SLC18A2 solute carrier family 18 (vesicular monoamine), member 2 
206207_at CLC Charcot-Leyden crystal galectin 
206676_at CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 
207269_at DEFA4 defensin, alpha 4, corticostatin 
208304_at CCR3 chemokine (C-C motif) receptor 3 
209369_at ANXA3 annexin A3 
209395_at CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 
209710_at GATA2 GATA binding protein 2 
210244_at CAMP cathelicidin antimicrobial peptide 
210254_at MS4A3 
membrane-spanning 4-domains, subfamily A, member 3 (hematopoietic cell-
specific) 
210517_s_at AKAP12 A kinase (PRKA) anchor protein 12 
212531_at LCN2 lipocalin 2 
212768_s_at OLFM4 olfactomedin 4 
223670_s_at HEMGN hemogen 
227530_at AKAP12 A kinase (PRKA) anchor protein 12 
230381_at C1orf186 chromosome 1 open reading frame 186 
41469_at PI3 peptidase inhibitor 3, skin-derived 
This table shows the common DEGS between Contrasts #2 & #3 by the Affy Id, Genes 
Name & Gene Title. 
 
 
Interestingly, the same 23 DEGs that were common between Contrast #2 & 
Contrast #3 were also common when Contrast #4 was compared to Contrast #5, shown in 
Table 3.13.   
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Table 3.13. Comparison of DEGs Between Contrasts #4 & #5. 
Comparison between Contrast #4 and Contrast #5. 
1554892_a_at MS4A3 membrane-spanning 4-domains, subfamily A, member 3 (hematopoietic cell-specific) 
202018_s_at LTF lactotransferrin 
203691_at PI3 peptidase inhibitor 3, skin-derived 
205033_s_at DEFA1 /// DEFA1B /// DEFA3 defensin, alpha 1 /// defensin, alpha 1B /// defensin, alpha 3, neutrophil-specific 
205513_at TCN1 transcobalamin I (vitamin B12 binding protein, R binder family) 
205624_at CPA3 carboxypeptidase A3 (mast cell) 
206207_at CLC Charcot-Leyden crystal galectin 
206676_at CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 
207269_at DEFA4 defensin, alpha 4, corticostatin 
208304_at CCR3 chemokine (C-C motif) receptor 3 
209710_at GATA2 GATA binding protein 2 
210254_at MS4A3 membrane-spanning 4-domains, subfamily A, member 3 (hematopoietic cell-specific) 
210517_s_at AKAP12 A kinase (PRKA) anchor protein 12 
212225_at EIF1 eukaryotic translation initiation factor 1 
212531_at LCN2 lipocalin 2 
212926_at SMC5 structural maintenance of chromosomes 5 
213939_s_at RUFY3 RUN and FYVE domain containing 3 
222529_at SLC25A37 solute carrier family 25 (mitochondrial iron transporter), member 37 
222900_at NRIP3 nuclear receptor interacting protein 3 
227530_at AKAP12 A kinase (PRKA) anchor protein 12 
230381_at C1orf186 chromosome 1 open reading frame 186 
233227_at KIAA1109 KIAA1109 
41469_at PI3 peptidase inhibitor 3, skin-derived 
This table shows the common DEGS between Contrasts #4 & #5 by the Affy Id, Gene 
Name & Gene Title. 
 
 
 Surprisingly, then the freezing devices (rate-controlled freezer and CoolCell) were 
compared to each other by vacutainer type, there were no DEGs detected (Contrasts #6 
and #7).  
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Chapter IV 
Discussion 
 
Hypothesis 
Sodium heparin CPT vacutainers are what Biogen uses to collect whole blood for 
its multi-site clinical trials as a simpler and more consistent way to isolate PBMCs for 
biomarker discovery.  The Biobank at Biogen is interested in looking at the gene 
expression profiles of isolated, cryopreserved and thawed PBMCs when whole blood is 
collected in a sodium heparin vacutainer compared to a sodium heparin CPT vacutainer. 
This study will also look at the effect on PBMC gene expression profiles when two 
different freezing devices are used: programmable rate-controlled freezers & CoolCells. 
Both devices are commonly used to cryopreserve PBMCs; however, the CoolCells are 
simpler to operate, less expensive, don’t require liquid nitrogen to operate and they 
require less lab space compared to a rate-controlled freezer. As a result, Biogen has the 
clinical trial sites use CoolCells to cryopreserve the PBMCs. Based on this, it is important 
for Biogen to know if freezing PBMCs using a CoolCell device produces a different gene 
expression pattern than when a rate-controlled freezer is used, which is typically 
available in Biogen laboratories.  
 For my project, I expected to see differences in the gene expression patterns 
between the freshly isolated PBMCs from whole blood collected in sodium heparin 
vacutainer versus freshly isolated PBMCs from sodium heparin CPT vacutainers. 
Furthermore, I expected that fewer genes would be affected when freshly isolated 
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PBMCs were compared to sister aliquots that underwent the freezing process in a rate-
controlled freezer as compared to those that were placed inside a CoolCell device, all of 
which were stored in the freezer for 1 month before being thawed. 
 
PBMC Recovery 
 After cryopreserving PBMCs, typical cell recovery is > 80% of the total number 
of PBMCs initially cryopreserved. However, as seen in Table 3.2, it is apparent that the 
cell recovery for most of the cryopreserved PBMC samples is much less than 80%, the 
fresh PBMCs were immediately added to RLT lysis buffer so recovery determination was 
not relevant.  The Vi-CELL was used to count all of the fresh cell aliquots and most of 
the cryopreserved cell aliquots used in this study since this machine is known to be 
accurate and it saves the user a lot of time compared to manually counting cells.  
 For Biogen’s clinical trials, the Biobank was required to use the Vi-CELL to 
count the cells and also to manually count the cells using a hemocytometer. It was 
noticed that for the same sample the number of cells manually counted using a 
hemocytometer were much lower than the cell counts produced on the Vi-CELL. Due to 
the low cell recoveries for the samples in this thesis research study and other studies, it 
became apparent that the Vi-CELL was malfunctioning as it was counting more viable 
cells than there actually were. The malfunctioning ViCELL did have a negative effect on 
my thesis research study as I was using a lot less cells than were needed, so in the end 
much less RNA was produced than what was needed for downstream processing.  More 
importantly when it was decided to use the backup samples to extract RNA, the backup 
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samples for 32 out of 60 samples were deemed unusable due to extremely low cell 
counts.  
 
Results of the Whole Blood Aliquots 
 Initially when this experiment was designed, it was decided that two 50 µl 
aliquots of whole blood would be taken from each vacutainer as soon as the blood was 
drawn. The whole blood would then be pooled into two 300 µl aliquots according to 
donor id and vacutainer type, RLT lysis buffer would be added to each aliquot and the 
samples would be frozen at -80°C. These samples were to be a type of “in vivo like” 
control that would provide a baseline gene expression profile for both mononuclear and 
polymorphonuclear cells in the whole blood exposed to the preservative but without any 
processing, i.e., ficoll density centrifugation, centrifugation or washing steps, that could 
affect the PBMC gene expression.  Unfortunately, RNA was not able to be extracted 
using the RNeasy Mini Kit from the whole blood samples collected directly from the 2 
vacutainer types, i.e., Sodium Heparin and Sodium Heparin CPT. Qiagen did not 
recommend the RNeasy Mini Kit for the isolation of RNA from whole blood but since 
the RNeasy Mini Kit was used for all of the PBMC-containing samples, the extraction of 
whole blood was attempted for consistency. Hence this Contrast is not presented in Table 
3.6 because it was not possible to generate these “in vivo like” control samples due to the 
incompatibly of the RNA extraction kit with the starting biological material, i.e., whole 
blood. 
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DNA Contamination Issues 
 The DNA contamination issue was the biggest set back as far as this thesis 
research study was concerned. This issue caused us to spend an entire month to 
troubleshoot. Over the course of the one-month period, 4 different RNA extraction kits 
were tested with the end goal of eliminating the DNA contamination issue. It quickly 
became apparent that the RNeasy Mini Plus kit was the best option since as it contains a 
genomic DNA eliminator column, which in turn produced the purist RNA.  
 While performing the DNA contamination experiments it was determined that the 
Bioanalyzer was malfunctioning. The issue was brought to our attention after RNA was 
extracted from the first set of cell aliquots, run on the Bioanalyzer twice to confirm that 
the RNA was of high quality and the RIN scores produced between the two runs were 
drastically different. Only 45% (27/60) of the RNA samples in the first Bioanalyzer run 
had a RIN >7, so samples were evaluated a second time. In the second Bioanalyzer run, 
only 45% of the RNA samples had a RIN >7. In most cases if a sample had a RIN >7 in 
the first run, it did not have a RIN >7 in the second run and overall there were 
considerable differences in the actual RIN scores of each sample between the first run 
and the second run. We initially thought that the discrepancies in the RIN scores could be 
due to DNA contamination so the Bioanalyzer was used for the DNA contamination 
evaluation.  
An experiment was performed using the mouse fibroblast cell line, M2-10B4 in 
which the mouse cells had their RNA extracted using four different RNA extraction kits 
and then the samples were run on the Trinean and the Bioanalyzer.  
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The results showed that the RNA extracted using the RNeasy Mini Plus kit was 
very pure even though a RIN score was only determined for 2 of 4 samples. The fact that 
the two unreadable mouse RNA samples were run on the same Bioanalyzer chip that 
failed supported the suspicion that it was due to an equipment problem and not a 
specimen quality problem, even though the Biobank’s Bioanalyzer had regular 
preventative maintenance. There were also RNA samples extracted from 10 PBMC 
samples isolated from the whole blood of healthy individuals that participated in the 
Biogen biospecimen donor program whose data was not shown.  These additionally 
isolated human PBMC samples supported the conclusion that a DNase treatment was 
needed to improve the quality of the RNA and that the Biobank Bioanalyzer may be 
problematic. 
Due to the inconclusive Bioanalyzer results, an additional experiment was 
performed using the mouse cells and PBMCs isolated from whole blood stored in sodium 
heparin vacutainers from Biogen’s volunteer donor program. The second experiment was 
performed so that RNA samples could be created to run on the Biobank’s Bioanalyzer 
and on the Molecular Lab’s Bioanalyzer to determine if the Biobank’s Bioanalyzer was 
functioning properly. The Biobank’s Bioanalyzer did not call a RIN score for any of the 
samples, and even though the samples were extracted with the RNeasy Plus Mini kit the 
samples did not appear to be very pure which is unusual for this kit. The Molecular Lab’s 
Bioanalyzer called a high RIN score for all of the samples and the samples appeared to be 
very pure. This experiment showed that even though the Biobank’s Bioanalyzer had 
regular preventative maintenance, it was not operating correctly, it was a source of the 
inconsistent RIN scores that were obtained and it should not be used for any future 
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evaluation until a complete diagnostic evaluation is performed by a qualified technical 
representative. 
 
Gene Expression Results of Vacutainer Types 
 I initially hypothesized that I would see differences in the gene expression 
patterns between freshly isolated PBMCs collected in sodium heparin vacutainers versus 
freshly isolated PBMCs collected in sodium heparin CPT vacutainers. One reason for my 
hypothesis is that sodium heparin vacutainers only contain sodium heparin while the 
sodium heparin CPT vacutainers contain sodium heparin and a cell separation medium. 
The second reason is that the sodium heparin vacutainers use ficoll density centrifugation 
to isolate the PBMCs from the whole blood while the sodium heparin CPT vacutainers 
simply use centrifugation.  
 The results of this thesis research study revealed that in Contrast #1, comparing 
freshly isolated PBMCs collected in sodium heparin vacutainers versus freshly isolated 
PBMCs collected in sodium heparin CPT vacutainers 21DEGs were identified. This 
number is much higher than I had anticipated given the fact that both vacutainer types 
contain the same preservative; however these results support my hypothesis. The 21 
DEGs indicates that PBMCs isolated from these 2 vacutainer types do not have identical 
gene expression patterns.  Even though both vacutainers contain sodium heparin, the 
sodium heparin CPT vacutainers have at least one known additional solution, i.e., cell 
separation medium, which may be responsible for the 21 DEGs that were identified but 
additional research is needed to address exactly what sample handling event was 
responsible. Likewise, looking at the 21 individual genes that are affected, it is not 
possible at this time to determine which of these DEGs are significant. 
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 Ruitenberg et al. (2006) processed the same vacutainer types that were processed 
in this thesis research study; sodium heparin CPT vacutainers and sodium heparin 
vacutainers.  Ruitenberg et al. (2006) results suggested that with fresh blood samples, 
samples processed with ficoll density centrifugation had a significantly better viability 
compared to sodium heparin CPT vacutainers processed PBMCs, but this was the 
opposite with cryopreserved samples as the sodium heparin CPT processed PBMCs had a 
better viability than the ficoll density centrifugation processed PBMCs although the 
difference was not significant. These researchers also concluded that regardless of the 
vacutainer type used, the fresh and cryopreserved PBMCs recoveries were not 
significantly different. It was concluded that regardless of whether fresh samples or 
cryopreserved samples are used, sodium heparin CPT vacutainers are in fact a very 
effective method for obtaining functionally active PBMCs, at least for HIV seropositive 
patients.  
  Ruitenberg et al. (2006) focused on cell viability and cell recovery, due to the Vi-
CELL malfunctioning my cell viability and cell recoveries were affected so I am unable 
to make a comparison to their results. Also, Ruitenberg et al. (2006) concluded that 
sodium heparin CPT vacutainers were acceptable to use regardless of if the PBMCs were 
fresh or cryopreserved. My results revealed that 21 DEGs were identified when 
comparing fresh PBMCs between both vacutainer types. More research into the 21 DEGs 
as we are unable to conclude what significance of any these genes have.  
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Gene Expression Results of Freezing Methods 
 The results of this thesis research study revealed that zero genes were 
differentially expressed when comparing thawed PBMCs collected in sodium heparin 
vacutainers and cryopreserved in a CoolCell device versus!thawed PBMCs collected in 
sodium heparin vacutainers and cryopreserved in a rate-controlled freezer. Similarly, zero 
genes were differentially expressed when comparing thawed PBMCs collected in sodium 
heparin CPT vacutainers and cryopreserved in a CoolCell device!versus!thawed PBMCs 
collected in sodium heparin CPT vacutainers and cryopreserved in a rate-controlled 
freezer. These results suggest that the gene expression profiles are not affected regardless 
if a rate-controlled freezer or a CoolCell device is used . It is important to note that the 
gene expression profiles were not affected when comparing the same vacutainer type 
with both freezing methods. We did not look at the following comparisons but we will 
look at them in the future: 
 1). Thawed PBMCs collected in sodium heparin CPT vacutainers and  
  cryopreserved in a CoolCell device!versus!thawed PBMCs collected in sodium 
  heparin vacutainers and cryopreserved in a CoolCell device. 
 2). Thawed PBMCs collected in sodium heparin CPT vacutainers and  
  cryopreserved in a rate-controlled freezer versus!thawed PBMCs collected in 
  sodium heparin vacutainers and cryopreserved in a rate-controlled freezer. 
 3). Thawed PBMCs collected in sodium heparin CPT vacutainers and  
  cryopreserved in a CoolCell device!versus!thawed PBMCs collected in sodium 
  heparin vacutainers and cryopreserved in a rate-controlled freezer. 
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 4). Thawed PBMCs collected in sodium heparin CPT vacutainers and  
  cryopreserved in a rate-controlled freezer!versus!thawed PBMCs collected in 
  sodium heparin vacutainers and cryopreserved in a CoolCell device. 
These results were initially promising since using a CoolCell is less time consuming and 
less expensive to provide these to hundreds of clinical sites. This also suggests that the 
clinical trial sites using CoolCells will not be negatively affecting the gene expression 
profiles of the samples that they collect, which is especially critical when dealing with 
biomarker discovery.  !
 However, in Contrast #2, comparing freshly isolated PBMCs collected in sodium 
heparin vacutainers versus thawed PBMCs collected in sodium heparin vacutainers and 
cryopreserved in a CoolCell device, 50 genes were differentially expressed.  In Contrast 
#3, comparing freshly isolated PBMCs collected in sodium heparin vacutainers!versus!
thawed PBMCs collected in sodium heparin vacutainers and cryopreserved in a rate-
controlled freezer, 23 genes were differentially expressed. The same 23 DEGs (100% 
agreement) that occurred when a rate-controlled freezer was used to cryopreserve the 
PBMCs was part of the 50 DEGs that occurred when the CoolCell was used. This is 
interesting since both devices cool PBMCs at the same rate of -1oC/minute.  Also both 
Contrast #2 and #3 used PBMCs that were isolated from sodium heparin vacutainers and 
were processed identically except for the cryopreservation device. This shows how 
important it is not to perform assays with a mixture of freshly isolated and cryopreserved 
PBMC samples even though the PBMCs were collected and isolated from the same 
vacutainer type.  Also researchers that need to use cryopreserved PBMCs from multiple 
studies need to check the sample annotation that resides in a biobank’s inventory system 
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to ensure that the selected PBMCs were cryopreserved using the same freezing device to 
avoid the differences in possible DEGs.!
 Similarly in Contrast #4, comparing freshly isolated PBMCs collected in sodium 
heparin CPT vacutainers versus thawed PBMCs collected in sodium heparin CPT 
vacutainers and cryopreserved in a CoolCell device, 48 genes were differentially 
expressed. In Contrast #5, comparing freshly isolated PBMCs collected in sodium 
heparin CPT vacutainers!versus!thawed PBMCs collected in sodium heparin CPT 
vacutainers and cryopreserved in a rate-controlled freezer, 29 genes were differentially 
expressed. Again, there were fewer DEGs occurring with thawed cryopreserved PBMCs 
when a rate-controlled freezer was used than when a CoolCell was used. 
 When the DEGs obtained from Contrast #3 were compared to the DEGs obtained 
from Contrast #5, there was very good agreement between the 2 sets of PBMCs samples 
that both used the rate-controlled freezer.  Of the 23 DEGs that occurred in Contrast #3, 
21 (91% agreement) of these were identical to what occurred in Contrast #5, regardless of 
which vacutainer was used to collect the whole blood.  However, there were no DEGs 
common between Contrast #1 and Contrasts #3 and #5, suggesting that the DEGs 
common to Contrasts #3 and #5 were related to the freezing or thawing process. In 
addition when all Contrasts #2 – #5 were compared, there were 17 of the 23 DEGs that 
were common (74% agreement). The importance of these DEGs needs further research 
but may be more cryopreservation relevant. 
Lastly, when the freezing devices (rate-controlled freezer and CoolCell) were 
compared to each other by vacutainer type, there were no DEGs detected (Contrasts #6 
and #7).  This is in contrast to what was found when Contrasts #2 and #3 were compared 
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and Contrasts #4 and #5 were compared, which indicated that there were more DEGs 
identified when a CoolCell was used.  It is important to stress that Contrasts #6 & #7 
focus on comparing thawed cryopreserved PBMCs to thawed cryopreserved PBMCs 
while Contrasts #2-#5 focus on comparing freshly isolated PBMCs to thawed 
cryopreserved PBMCs which could explain the difference in results. This observation 
needs further investigation. In general, the largest changes in gene expression of the 
PBMCs occurred from freshly isolated PBMCs when compared between the 2 vacutainer 
types (Contrast #1). 
Interestingly, Lempicki et al., (2013), actually cultured some of their thawed 
cryopreserved PBMCs for 24 hours before analyzing the gene expression profiles. 
Lempicki et al., (2013) gene expression analysis revealed that genes in the Cluster 1, 2, 
and 3, (these genes are involved in defense response), revealed similar gene expression 
profiles before and after the PBMCs were cultured for 24 hours while genes in cluster 4 
and 5, (these genes are enriched and they are involved in general cell metabolism) 
revealed that the gene expression profiles could be rescued by culturing the PBMCs for 
24 hours.  Based on the results that Lempicki et al., (2013) found it may be valuable for 
researchers to consider culturing cryopreserved PBMCs to rescue the gene expression 
profiles before running the samples on their desired assays. It may be possible that 
culturing the PBMCs and allowing the gene expression profiles to adjust could help 
decrease background or cryopreservation affects  as compared to when the researchers 
thaw and run the PBMCs on their assays immediately.  Of course, culturing PBMCs may 
also introduce DEGs that would need to be identified and properly accounted for when 
interpreting the data.  
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 As part of this study I hypothesized that fewer genes would be affected when 
freshly isolated PBMCs were compared to sister aliquots that either underwent the 
freezing process in a rate-controlled freezer or a CoolCell device, all of which were 
stored for 1 month before being thawed. It seems as though regardless of the vacutainer 
type, when comparing PBMCs frozen using a CoolCell to Fresh cells about 50 
differentially expressed genes are present.  Again regardless of the vacutainer type, when 
comparing PBMCs frozen using a rate-controlled freezer to fresh cells close to 30 genes 
were differentially expressed. These comparisons suggest that my hypothesis was correct 
given the fact that that almost twice as many genes were expressed when comparing cells 
frozen in a CoolCell device to fresh cells versus cells frozen in a rate-controlled freezer to 
fresh cells.  
 
Comparing Gene Expression in Lempicki et al. 2013  
 I compared all of the differentially expressed genes in my study to the ones 
expressed in Lempicki et al. 2013, and only 3 genes are shared. These 3 genes are LTF, 
DEFA1 & DEFA4, all of these genes are involved in the defense response. There were a 
few differences between the way Lempicki et al. 2013 and I handled/processed the 
samples, which could account for the difference in the gene expression profiles.  
Lempicki et al. 2013 froze their samples for 14 months before the gene expression arrays 
were run on the samples but I only froze the samples for 1 month due to the 9 month time 
constraint to complete this thesis. All of Lempicki et al. 2013 samples were frozen using 
a rate-controlled freezer whereas I used a CoolCell device and a rate-controlled freezer. 
Lempicki et al. 2013 used a different extraction kit, all of their samples were extracted 
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with RNeasy Mini Kit without a DNase treatment, this was the kit I initially used but it 
did not work well for me. Lastly, Lempicki et al. 2013 used Acid Citrate Dextrose 
vacutainers but I used sodium heparin CPT vacutainers and sodium heparin vacutainers 
because these two vacutainer types are used by Biogen. 
 
Future Experiments 
 In order to confirm the gene expression data from this study, RT-PCR needs to be 
performed.  Unfortunately, the RT-PCR is currently being performed but we do not have 
the results yet. However, the genes for the RT-PCR were chosen based on the gene 
expression results from Lempicki et al., 2013. Therefore the RT-PCR will most likely 
need to be repeated using a different set of genes since only 3 genes expressed in this 
research overlapped with the gene expression results from Lempicki et al., 2013.  
 An additional experiment was performed in which whole blood in CPT tubes was 
collected, the PBMCs were isolated and then the PBMCs were washed several times 
using four different wash buffers; PBS only, PBS + 10% FCS, RPMI-1640 only & 
RPMI-1640 + 10% FCS. Each of Biogen’s clinical trials uses a different wash buffer so it 
is important to the company to determine if the wash buffers being used have an effect on 
the gene expression profiles. Also it is important to look at the cell viability using the 
different wash buffers since some media contain more nutrients for cells than others. The 
gene expression data was recently produced but it still needs to be analyzed. 
 Lastly, in the future we would like to perform a similar type of experiment but 
this time we would like to focus on the gene expression profiles of PBMCs when 
different cryococktails are used for cryopreservation. Each of Biogen’s clinical trials uses 
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a different cryococktail so it is important to the company to determine if the cryococktails 
being used have an effect on the gene expression profiles. More importantly it would be 
beneficial for the company to find a cryococktail that minimally alters the gene 
expression profiles especially when using the samples for biomarker discovery. Some of 
the different cryococktails we are interested to test are: 1). 72.5% RPMI-1640, 20% FCS 
& 7.5% DMSO 2). 90% FCS & 10% DMSO.  
 
Conclusions 
 Overall, the goal of this thesis research study was to provide scientific 
information using gene expression analysis to establish “Best Practices” for collecting, 
isolating, processing and cryopreserving human PBMCs. The results of this thesis 
research study suggest that using fresh cells is better than cryopreserving cells; however 
this is not typically always an option in the lab. If cryopreservation is needed, CoolCell 
devices and rate-controlled freezers are both solid options. But if the goal is to have the 
gene expression profile be as close to the gene expression profile of fresh cells as 
possible then a rate-control freezer should be used. Lastly, it seems as though sodium 
heparin CPT vacutainers and sodium heparin vacutainers are both acceptable choices 
when isolating PBMCs from whole blood.  However, based on my gene expression data 
there are differences that can result and it will be important for the researcher to check the 
sample processing that was done to determine if it could affect her/his research especially 
when samples could be obtained across multiple studies whose sample processing is 
known to be different.   
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